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„You can't connect the dots looking forward. You can only connect 
them looking backwards, so you have to trust that the dots will 
somehow connect in your future“ 
Steve Jobs 
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1 Introduction 
1.1 The burden of asthma 
Asthma is a highly prevalent disease that affects 330 million individuals in the 
world. During the past 60 years, the incidence and severity of asthma have constantly 
increased. Great attention has been aroused by scientsists and much effort has been put 
into investigation in both patients and animal models. It is becoming recognized that 
allergic asthma is a multifactoral disease of gene-environment interaction (Renz et al., 
2011; Mukherjee et al., 2011). Novel phenotypes of asthma such as non-eosinophilic 
asthma has been identified and current therapy which focuses on the inhibition of Th2 
cell-mediated eosinophilic airway inflammation is not sufficient for the treatment of 
new phenotypes. There is an urgent need to uncover the underlying pathogenesis of 
different asthma phenotypes, which serves to the direction of appropriate and effective 
treatment of asthma disease. 
1.2 The definition of asthma 
What is asthma? The Global Initiative for Asthma (GINA) (Bateman et al., 2008) 
and the National Heart, Blood and Lung Institute (EPR-3, 2007) describes asthma as 
follows: 
“Asthma is a chronic inflammatory disorder of the airways in which many cells and 
cellular elements play a role, in particular, mast cells, eosinophils, T-lymphocytes, 
macrophages, neutrophils and epithelial cells. In susceptible individuals, this 
inflammation causes recurrent episodes of wheezing, breathlessness, chest tightness, 
and coughing, particularly at night or in the early morning. These episodes are usually 
associated with widespread but variable airflow obstruction within the lung that is often 
reversible either spontaneously or with treatment. The inflammation also causes an 
associated increase in the existing bronchial hyperresponsiveness to a variety of stimuli. 
Reversibility of airflow limitation may be incomplete in some patients with asthma”.  
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To be brief, asthma has three main features: airflow obstruction, bronchial 
hyperresponsiveness, and an underlying inflammation. Interactions between these 
features determine the clinical manifestations and severity of asthma (Figure 1.1) and 
the response to treatment. 
 
 
 
Figure 1.1 Interactions between airway inflammation and the clinical symptoms and 
pathophysiology of asthma (EPR-3, 2007) 
However, the concepts underlying asthma pathogenesis have been renewed 
tremendously in the past years and are still undergoing updation because various 
phenotypes of this disease are identified. A better understanding of this disease requires 
a detailed interpretation of genetic patterns, environmental substances or other factors 
which are responsible for various clinical manifestations or different subtypes of asthma 
(Busse et al., 2001).  
1.2.1 Asthma phenotyping 
Asthma has long been considered as a heterogeneous disease, which consists of 
different phenotypes. The term phenotype refers to “the visible characteristics of an 
organism resulting from the interaction between its genetic makeup and the 
environment” (Wenzel, 2006). Clinically, asthma phenotypes represent the individual 
differences of disease which are directly related to meaningful outcomes, for example, 
the response to treatment, rate of progression, prognosis of disease, etc. Therefore it’s of 
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importance to identify a patient’s asthma phenotype for the benefit of treatment. Up to 
now, many categories have been employed to define asthma phenotypes, since asthma is 
likely to be comprised of overlapping syndromes with multioriginal pathobiology. The 
categories are mostly based on etiologic factors (eg. aspirin sensitivity, persistent 
respiratory infections, occupational irritants, or toxic exposures), clinical features (eg. 
mild, severe, brittle, near fatal, with fixed airflow limitation, steroid resistant), 
inflammation type (eosinophilic, non-eosinophilic) or gene expression signature 
(Th2-high, Th2-low) (Wenzel, 2006; Bel, 2004; Woodruff et al., 2009; Bradding et al., 
2010). Among all the defined phenotypes, non-eosinophilic asthma is a relatively new 
phenotype which was first identified by Green’s group (Green et al., 2002). In their 
studies, a distinct subgroup (23% asthma patients) had a sputum cell profile with 
increased neutrophils but no eosinophils. Such patients with a neutrophil-dominated 
sputum responded less well to inhaled corticosteroids than those with an 
eosinophil-dominated sputum. Up to now, a specific management for non-eosinophil 
asthma phenotype is still lacking. Further phenotyping of asthma provides a vital 
stimulus for the development of novel therapeutic agents or prevention concepts, 
thereby improving our insight into the pathogenesis of asthma. A detailed asthma 
phenotyping is also encouraged by the availability of new therapies. 
1.2.2 Pathophysiological mechanisms in the development of airway inflammation 
From the definition of asthma, we know that inflammation plays a critical role in 
the pathophysiology of asthma. As shown in Figure 1.2, airway inflammation involves 
an interaction of many cell types and multiple mediators within the airways which 
eventually results in the characteristic pathophysiological features of the disease: 
bronchial inflammation and airflow limitation that give rise to recurrent episodes of 
cough, wheeze, and shortness of breath. The processes by which these interactive events 
occur and lead to clinical asthma are still under investigation. In addition, although 
distinct phenotypes of asthma exist, airway inflammation remains a consistent pattern. 
The pattern of airway inflammation in asthma, however, does not necessarily vary 
depending upon disease severity, persistence, and duration of disease. The cellular 
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profile and the response of the structural cells in asthma are quite consistent. 
 
 
Figure 1.2 Asthma is a multicellular disease of airway inflammation (Lloyd et al., 2010) 
   
 
1.2.3 Mast cells 
Mast cells play an essential role in the initiation of allergic (extrinsic) asthma by 
virtue of their expression of high-affinity IgE receptor, FceRI (Bradding et al., 2006; 
Andersson et al., 2011). Increased numbers of bronchial mast cells and elevated levels 
of IgE have been described in allergic asthma, which is triggered by inhaled allergens 
such as house dust mite, pet dander, pollen proteins, and mold spores (Kearley et al., 
2011; Andersson et al., 2011; Goplen et al., 2009; Fairs et al., 2010). When exposed to 
the allergens, mast cells dergranulate and secrete histamine, prostaglandin D2 and 
leukotriene C4, cytokines and protease in the airways, which contributes to an early 
asthmatic reaction (EAR) with bronchoconstriction vasodilatation and mucus 
production (Woodman et al., 2008; Saha et al., 2009). 
Many cells including mast cells, eosinophils, lymphocytes, neutrophils, dendritic cells and epithelial 
cells are involved in the pathogenesis of asthma. 
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1.2.4 Eosinophils 
Eosinophils come to rise in the late asthmatic reaction (LAR). They accumulate in 
the airways of most asthmatic patients to constitute airway inflammation (Williams, 
2004). The activated eosinophils release a number of cytotoxic molecules including 
major basic protein (MBP) and eosinophil peroxidase (EPO), which are responsible for 
the induction of bronchoconstriction and airway hyperresponsiveness (AHR), and 
produce cytokines such as IL-5. IL-5 is extremely important for the maturation of 
eosinophils. It acts on eosinophils to promote terminal differentiation of 
eosinophil-lineage committed precursors and together with the chemokine eotaxin leads 
to eosinophil recruitment to sites of inflammation. IL-5 also prolongs eosinophil 
survival (Kariyawasam et al., 2007). Besides inflammation, the activated eosinophils 
are also implicated in airway remodeling, because they serve as a significant source of 
TGF-β1 in asthmatic patients. TGF-β1 mediates airway remodeling by promoting the 
differentiation of fibroblasts to myofibroblasts that secrete extracellular matrix proteins 
(ECM), and stimulates airway smooth muscle hyperplasia via the Mitogen-activated 
protein kinase (MAPK) pathway (Kariyawasam et al., 2007; Halwani et al., 2011). 
1.2.5 Lymphocytes 
Asthma is more recognized as a T helper 2 (Th2) cell-mediated disease, because the 
production of Th2 cytokines (such as IL-4, IL-5 and IL-13) is responsible for the key 
pathophysiological features of asthma. Whereas IL-4 accounts for allergic sensitization 
and promotes Ig isotype switching in B cells to produce primarily IgE and IgG1, IL-5 is 
crucial for the presence of eosinophils, and IL-13 induces goblet cell hyperplasia (GCH) 
and airway hyperresponsiveness (Neveu et al., 2009). IL-25 is another Th2 cytokine 
described as a potentiator of Th2 memory responses. The finding that IL-25 activates 
eosinophils to produce a range of asthma-relevant mediators such as IL-8 suggests that 
IL-25 may play a pivotal role in maintaining Th2 central memory and sustaining 
asthmatic inflammation (Wong et al., 2005). Because of the widely-accepted Th1-Th2 
paradigm, Th1 cells might be expected to be inhibitory of asthmatic airway 
inflammation. High levels of IFN-γ are expressed by Th1 cells, which have a critical 
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function in regulating the proliferation and apoptosis of T lymphocytes by upregulating 
the expression of Fas protein on T cell surfaces (Dalton et al., 2000; De Rose et al., 
2004). It was demonstrated that apoptosis of Th1 cells, particularly in a high 
IFN-γ-producing fraction of T cells, is much more prominent in atopic patients 
compared with healthy controls as a mechanism of Th2 predominance (Akkoc et al., 
2008). However, Th1 cells can become pathological super Th1 cells, which induce AHR 
and lung fibrosis by production of IFN-γ and IL-13 in the mouse model of bronchial 
asthma (Hayashi et al., 2007). Another T cell subset, regulatory T (Treg) cells, which act 
as the regulator of the effector class of the immune response, probably mediate the 
orchestration of Th1/Th2 balance whose defect could lead to the pathological expansion 
of Th2 cells in allergic asthma (Corthay A, 2009; Finotto, 2008). Other T cell subsets, 
such as Th17 cells, Th9 cells and Th22 cells have emerged and extended the existing 
Th1-Th2 paradigm. These T cells are the main members in the adaptive immune system 
and elicit unique responses to many immunological insults which they encounter. As 
depicted in Figure 1.2, the activated T cells produce specific cytokines, interact with 
other cells, and promote different types of inflammatory responses against different 
allergens. The variability and diversity of immune responses predict the complexity of 
asthma pathogenesis.  
1.2.6 Neutrophils 
Neutrophils play an immediate role in the immune defense against bacterial and 
fungal infections by a quick arrival at and a fast remove from inflammation sites 
(Monteseirín, 2009). Because of the immediate effect, neutrophils are not detectable at a 
later time point and no difference is found in the number of BAL neutrophils between 
asthmatic patients and normal control (Boulet et al., 1993). The role of neutrophils in 
the pathogenesis of asthma is underestimated. However, it should be noted that around 
50% of asthmatic patients present noneosinophilic inflammation (Al Heialy et al., 2011; 
Monteseirín, 2009; Douwes et al., 2002). Most cases are associated with an increase of 
neutrophils in the airway submucosa. In chronic severe asthma, airway neutrophilia 
even becomes a recognised feature (Uddin et al., 2010). Because of the immediate effect, 
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neutrophils may be an ideal candidate for controlling the recruitment of other cell types 
(eg. dentritic cells) to the inflammation sites. Activated neutrophils release a set of 
chemokines, including IL-8 and growth-related oncogene α (GRO-α), which are 
chemoattractants for neutrophils. It forms a positive feedback loop for the accumulation 
of neutrophils (Monteseirín, 2009). Further studies are needed to explore the 
interactions between neutrophils and other cells and their integrated effect in the 
pathogenesis of asthma. 
1.2.7 Dendritic cells 
It is known that dendritic cells bridge innate and adaptive immunity in the 
pathogenesis of asthma (Lambrecht et al., 2009). In the lung, there are at least five 
subtypes of dendritic cells (DCs). They are distributed throughout the lung and trigger 
innate immune responses by taking up inhaled allergens. During the processing of 
allergens, DCs migrate to the draining lymph nodes. They express costimulatory 
molecules such as CD86 and high levels of MHC class II, which induce the 
proliferation of naïve T cells. They produce the chemokines CCL17 and CCL22, which 
bind to CCR4+ Th2 cells and recruit them to inflammation sites. Lung DCs are the main 
antigen-presenting cells (APCs) which initiate Th2 immune response during airway 
inflammation. This has been demonstrated by using an OVA-induced asthma model, in 
which Th2 cells do not produce IL-4, IL-5 or IL-13 in the absence of CD11c+ DCs (van 
Rijt et al., 2005).  
1.2.8 Epithelial cells 
 The airway epithelium lining the upper airways acts as the interface between 
external and internal environments and provides the first line of defense against inhaled 
pathogens in innate immunity by producing inflammatory mediators and activating 
inflammatory cells. Epithelial cells are a major source for eotaxin, an eosinophil specific 
chemokine which recruits eosinophils from the blood into the lung. Eotaxin recognizes 
the sole receptor CCR3, which is expressed on eosinophils and Th2 cells involved in 
allergic responses. Together with IL-5, eotaxin makes up a two-step mechanism which 
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explains the development of tissue eosinophilia in vivo (Rothenberg et al., 1996). 
Epithelial cells can release KC (keratinocyte chemokine), also named CXCL1, which 
activates and recruits neutrophils within the airways contributing to the pathogenesis 
and severity of asthma and other respiratory diseases. Moreover, the notion that 
epithelial cells participate in asthma pathogenesis is reinforced by their secretion of 
CCL17 and TSLP (Thymic stromal lymphopoietin), which attract Th2 cells and promote 
Th2 cell differentiation, respectively (Heijink et al., 2007; Ying et al., 2005).        
1.3 Innate and adaptive immunity in asthma 
The initiation of allergen sensitivity occurs at mucosal contact surfaces, where 
innate immunity provides a powerful early defense. A broad range of innate immune 
cells participate in this defense, including epithelial cells, dendritic cells, macrophages, 
neutrophils and natural killer T cells. All these cells function to block the entry of 
microbes by recognizing innate molecule pattern recognition receptors (PRRs) such as 
Toll-like receptors (TLRs), Nod-like receptors (NLRs), and C-type lectin receptors. The 
receptors recognize not only microbial products, but also cytokines like IFNγ, which 
enhances the ability to phagocytise microbes by innate immune cells. Adaptive 
immunity is also called acquired immunity, of which the two adaptive immune cells, T- 
and B-lymphocytes, are both implicated in asthma. T cells recognize antigens presented 
by antigen presenting cells (APC cells), and mediate cell immunity by releasing 
different cytokines. For example, Th17 cells secrete IL-17, a cytokine recognized as 
pro-inflammatory in allergic responses. The other T cells, Th1, Th2, Treg, Th9, and 
Th22 cells, which are briefly described in Chapter 1.2.5, contribute to asthma 
pathogenesis as well. Meanwhile, B cells mediate humoral immunity by producing 
antibodies such as IgE, which is suggestive of allergic immune response. It is becoming 
clear both innate and adaptive immunity have crucial roles in the development of 
asthma. In fact, innate and adaptive immunity are not mutually isolated, instead, they 
synergize with each other. On one hand, innate immunity directs the way that adaptive 
immune system responds to allergens. On the other hand, adaptive immunity combats 
microbes which have evaded innate immunity. The combined activation of both innate 
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and acquired immune response may account for a mixed inflammation of eosinophils 
and neutrophils in some patients of acute asthma (Douwes et al., 2002). 
1.4 The “Hygiene hypothesis” 
The “Hygiene hypothesis” was formulated in the case that allergic diseases have 
been increasing in the industrialized world with improved environmental living 
conditions. It was initially proposed by Strachan, who observed an inverse correlation 
between hay fever and the number of older siblings when following more than 17,000 
British children born in 1958 (Strachan, 1989; Okada et al., 2010). The hypothesis states 
that modern health care and hygiene practices have led to a relative sterilization of the 
environment with diminished exposure to bacterial, viral or fungal components. Under 
such circumstances, the potential allergy-preventing ability of the microbial factors 
reduces or no longer exists. As a result, there is an imbalance of the immune system 
which predisposes individuals to the development of allergic diseases (Renz et al., 2006; 
Garn et al., 2007). This hypothesis was subsequently confirmed by several 
epidemiological studies and immunologic results. For example, in a study which 
assessed the relationship between exposure to pets in the early years of life and allergic 
sensitization, it was found that exposure to pets during infancy might have a protective 
effect later on in life (Hesselmar et al., 1999). In line with this point, antibiotic use in 
early childhood has been associated with an increased risk of developing asthma. The 
immunological explanation for this phenomenon is due to the dynamic nature of the 
immune system. In this system, immune response genes are more easily targeted and 
evolvable for the adaptation to a highly changeable and complexed environment than 
those involved in other biological processes such as cell growth (Sironi et al., 2010). 
The immune system is still under development in early life and appropriate exposure to 
allergic agents helps to shape the immune system. This evolutionary shaping role of 
allergens could also be shown in animal models. Nembrini and colleagues (Nembrini et 
al., 2011) have demonstrated that pulmonary exposure to the bacterium Escherichia coli 
(E. coli) leads to a suppression of allergic airway inflammation in OVA-sensitized mice. 
In addition to E. coli, other microbes such as Bordetella pertussis (Kim et al., 2004), 
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Chlamydia
 (Han et al., 2004), Acinetobacter lwoffii F78 (A. lwoffii F78) (Conrad et al., 
2009; Brand et al., 2011) and Lactococcus lactis G121 (Debarry et al., 2007) have been 
shown to modulate allergic airway reactions or provide asthma protection. 
1.5 Murine asthma models 
Development of animal models is a feasible approach to explore the 
pathophysiology of diseases and potential discovery of novel therapeutics, since human 
experimentation is limited. Mice are the most common species studied in animal models 
of asthma. Mouse models of allergen exposure have been successfully designed to 
demonstrate the characteristic features of allergic asthma including airway inflammation, 
remodelling and airway hyperresponsiveness. Ovalbumin (OVA) derived from chicken 
egg is the most frequently used model allergen that induces a robust, allergic pulmonary 
inflammation in mice. Typically, it is injected intraperitoneally along with an adjuvant, 
aluminum hydroxide, which serves to improve the OVA’s immunogenicity for reasons 
that are complex and not entirely understood (Bates et al., 2009; Kool et al., 2008). 
After the immune system has had a chance to mount a reaction against the antigen 
protein, which takes several days, the animal receives a further antigen exposure either 
directly to the lungs in the form of an aerosol or via postnasal drip following intranasal 
instillation. This elicits an inflammatory reaction in the lungs characterized by an influx 
of eosinophils, epithelial thickening and AHR, which has been demonstrated in a variety 
of studies. Although the OVA-induced allergic airway inflammation model can 
represent many of the central features of allergic asthma, there are still some 
shortcomings, as listed in Table 1.1. The relevance of ovalbumin to human asthma and 
the attempt to sensitize the mice through airways have led to the use of house dust mite 
(HDM) extract.  
HDM represents one of the most common sources of aeroallergens worldwide. The 
mites are tiny (up to 0.3 mm) animals related to ticks and spiders, living in house dust 
and producing proteases which are highly allergic to the human being. Despite 
geographical differences, HDM allergens are related to 50-80% of asthmatics. The 
predominant species associated with human asthma are Dermatophagoides 
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pteronyssinus (Der p) and Dermatophagoides farinae (Der f), and their allergens have 
been divided into 19 groups (Der p 1-Der p 19, Der f 1-Der f 19). In recent years, HDM 
has been indicated of modeling asthma phenotype in different studies (Cates et al., 2004; 
Phipps et al., 2009) and has some advantages in mimicking human asthma (see Table 
1.1). Compared to OVA, HDM is a more naturally occurring and clinically relevant 
allergen, since OVA is not related to inducing any type of human asthma. The 
sensitization of HDM is without additional adjuvant. It is possible to sensitize the mice 
through the respiratory tract, which is likely the route of sensitization in humans. It is 
also suggested that sensitizing the mice with HDM for a long time can emulate some 
features of chronic asthma while chronic OVA exposure may lead to inhalation 
tolerance (Stevenson et al., 2011; Swirski et al., 2002). Therefore HDM is a more 
suitable allergen for asthma models and also the concern of this study.  
Table 1.1 Comparison of biological behaviors of OVA and HDM in murine asthma models 
 OVA HDM 
Mode of sensitization i.p., s.c. i.n., IA 
Dose usage 10 µg, 20 µg, 50 µg, 100 µg, 1000 
µg 
HDM extract: 25 µg, 50 µg, 100 µg 
Total protein: 2.5 µg, 5 µg, 10 µg, 20 µg, 
40 µg, 80 µg 
Adujvant Alum, B. pertussis, etc (-) 
Inflammatory cell 
types 
eosinophil, Th2 cell, Th1 cell, mast 
cell, dendritic cell, basophil 
neutrophil, eosinophil, Th2 cell, Th17 
cell, dendritic cell, basophil 
Immunoglobulins total IgE, OVA-specific IgE, IgG1, 
IgG2a 
total IgE, HDM-specific IgE, IgG1 
Lung histology GCH GCH 
AHR increased increased 
   
Note: i.p. refers to intraperitoneally; s.c. subcutaneuosly; i.n. intranasally; IA intratracheal aspiration; (-) no 
1.6 Hypothesis and aim of this study 
In recent years, exploration of the inverse relationship between microbial agents 
and allergic diseases becomes a hotspot in scientific research field. Several microbes 
including Bordetella pertussis, Chlamydia, A. lwoffii F78 and Lactococcus lactis have 
been shown to provide asthma protection in OVA models, in which eosinophil airway 
recruitment is inhibited. Due to the low amount of neutrophils in OVA asthma models, 
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the microbial effect on neutrophil inflammation or a mixed inflammation of neutrophils 
and eosinophils is underappreciated. Since noneosinophilic asthma constitutes a 
considerable part of asthma, it is in urgent need to clarify the relationship between 
microbes and neutrophils. Therefore, the hypothesis of this study is that administration 
of the bacterium Staphylococcus sciuri (S. sciuri) inhibits murine asthma phenotype 
with an airway inflammation dominated by neutrophils and eosinophils through 
education of the immune system.  
The aim in the first part of this study is to establish a murine asthma model with a 
mixed inflammation of airway neutrophils and eosinophils by using HDM extract. 
Although HDM has been universally regarded as a pivotal allergen, experimental data 
concerning asthma phenotype are still in controversy. One possible reason is that the 
biochemical properties of HDM extracts vary extensively among different preparations. 
The other explanation lies in the diverse doses of HDM extracts administrated in 
different studies. In this study, different origins, different doses of HDM extracts as well 
as different time points after the last sensitization of allergen are investigated in one 
mouse model successively. Through the examination of asthma-associated parameters, a 
detailed asthma phenotype will be delineated which consists of an inflammatory pattern, 
a profile of cytokine and chemokine expression and a subsequent change in serum 
immunoglobulins, lung histology and airway responsiveness. Furthermore, 
investigations of the underlying mechanisms for HDM-induced asthma phenotype are 
involved. 
In the second part of this study, the Gram-positive bacterium S. sciuri will be 
employed as a possible preventive strategy in this mouse model. This is the first time to 
investigate the influential role of S. sciuri in HDM-induced asthma phenotype. The 
bacteria are isolated from the dust of a farm cowshed, which have been indicated of a 
protective role in childhood asthma (Ege et al., 2011). In these experiments, the bacteria 
are administrated prior to HDM sensitization. Corresponding biological events are 
recorded in kinetics and the influence of S. sciuri on HDM-phenotype is determined. 
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2 Materials and methods 
2.1 Animals 
For in vivo animal experiments, female wild type (WT) BALB/c mice aged 5-6 
weeks were obtained from Harlan Winkelmann (Borchen, Germany). All mice were 
maintained under pathogen-free housing conditions. Water and food were supplied ad 
libitum. All experimental procedures were approved by the local animal ethics 
committee and met German and international guidelines. At least 4 mice were used per 
group. 
2.2 Induction of asthma phenotype by HDM extract 
House dust mite (HDM) extracts were obtained from Allergopharma Co. or Greer 
Labs. Mice were anaesthetized by using Ketamine/Rompun. According to protocol 1 
(Figure 2.1), anesthetized mice received an intranasal instillation of PBS or HDM 
extract (50 µg or 100 µg of the whole extract dissolved in 50 µl PBS) on days 0, 7, 14, 
21, 28, 35. Airway hyperresponsiveness was measured on day 36. 48 hours after the last 
challenge, the mice were sacrificed for further analysis. 
 
Figure 2.1 Protocol 1 for HDM-sensitized mouse model 
According to protocol 2 (Figure 2.2), on days 0, 7, 14, 21, the mice received an 
intranasal instillation of PBS or 100 µg HDM extract (Allergopharma Co.) in 50 µl PBS. 
24 and 48 hours after the final challenge, the mice were sacrificed respectively for 
further analysis. 
 
 
 
 
Figure 2.2 Protocol 2 for HDM-sensitized mouse model 
 
7 14 21 Day 0   
PBS or HDM (i.n.) 
28 35 
Analysis 
36 37 
23 22 7 14 21 Day 0   
Analysis PBS or HDM (i.n.) 
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Reagents: 
House Dust Mite Extract (Lot no. W0657678) Allergopharma Co, D 
House Dust Mite Extract (Lot no. 125118) Greer Labs, D 
House Dust Mite Extract (Lot no. 140153) Greer Labs, D 
PBS (Dulbecco´s Phosphate Buffered Saline) PAA Laboratoires GmbH, Cölbe, D 
2.3 Treatment of Staphylococcus sciuri in HDM-induced asthma 
For Staphylococcus sciuri (S. sciuri) treatment (protocol 3), the mice were given S. 
sciuri (108 CFU/25 µl) or PBS intranasally. It started nine days before the first 
sensitization, took place for 3 times in one week and lasted until the last challenge. 24 
and 48 hours after the final challenge, the mice were sacrificed respectively for further 
analysis (see Figure 2.3).  
 
Figure 2.3 Protocol 3 for treatment of Staphylococcus sciuri in HDM-sensitized mouse model 
 
 
Reagents: 
Staphylococcus sciuri Munich, D 
House Dust Mite (Lot no. W0657678) Allergopharmaco, D 
PBS (Dulbecco´s Phosphate Buffered Saline) PAA Laboratoires GmbH, Pasching, A 
2.4 Measurement of airway hyperresponsiveness by Head-out body 
plethysmography 
The Head-out body plethysmography measured standard lung function parameters 
like half-maximal expiratory and inspiratory flow, tidal volume, time of inspiration and 
expiration and respiratory rate on spontaneous breathing, non-anesthetized mice. 
Airway hyperresponsiveness (AHR) was measured one day after the last challenge of 
HDM extract and expressed as the concentration of methacholine (MCh50) which 
23 22 7 14 21 Day 0   
Analysis 
 19   16   14   12   9    7    5    2    0    (-2)   (-5)   (-7)  
PBS or  
PBS or HDM (i.n) 
 Day (-9)   
S.sciuri (i.n) 
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caused a 50% reduction in mid-expiratory airflow (EF50).  
The system consists of a glass Head-out body plethysmograph to which an aerosol 
exposure chamber is attached. For airflow measurement, the mice were positioned in the 
plethysmograph with the head sticking out of a neck collar (Φ 9 mm) into the ventilated 
exposure chamber. A calibrated pneumotachograph and a differential pressure 
transducer coupled to an amplifier were attached to the top port of the plethysmography. 
The respiratory movement from the mice will lead to a volume change in the 
plethysmograph and the resulting airflow is measured by the pneumotachograph. The 
amplified and digitized flow signals are intergrated with time to obtain tidal volume. 
From these data, the value of EF50 could be achieved by using the software Notocord 
hem 3.5. 
The measurement started with the determination of the baseline level, during which 
the mice respired 4000 times without any substances delivered to the head exposure 
chamber. All the values obtained at this time were averaged and the mean value was 
taken as 100%. The corresponding differentiations to the control data were regarded as 
deviations from the baseline. The measurement was continued by the addition of 
bronchoconstrictor methacholine (MCh). MCh was dissolved in PBS for different 
concentrations: 0 mg/mL, 12.5 mg/mL, 25 mg/mL, 50 mg/mL, 75 mg/mL and 100 
mg/mL. The solutions were delivered by a jet nebulizer to the head chamber every 5 
minutes in an increasing dose, and every delivery lasted 70 seconds. The resulting 
airway constriction from administration of MCh induced characteristic changes in the 
tidal flow pattern, which were best revealed by a decrease in tidal midexpiratory flow 
(EF50). Asthmatic mice are more sensitive to MCh compared to normal mice, thus with 
a lower MCh50 detected. 
Reagents: 
PBS (Dulbecco´s Phosphate Buffered Saline) PAA Laboratoires GmbH, Cölbe, D 
Methacholine Sigma, Taufkirchen, D 
Materials:  
Glass exposure chamber Forschungsstaetten, Medical School Hannover, D 
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Pneumotachograph PTM378/1.2 Hugo Sachs Elektronic, March-Hugstetten, D 
Pressure Transducer 8T-2 Gaeltec, Dunvegan, Scotland 
Amplifier HSE-IA Hugo Sachs Elektronic, D 
Notocord Hem 3.5 Software Notocord, Paris, France 
2.5 Acquisition of blood from animals 
After the mouse was injected with 200 µl 5х anesthetics (50 mg/ml Ketamine 10 
ml+ 2% Rompun 3.125 ml) intraperitoneally (i.p), skins under the axilla were cut out 
and around 0.5 ml blood from axillary vessels were collected. After coagulating at room 
temperature for one hour, the blood sample was centrifuged at 2000 rpm for 30 minutes 
at 4 °C. The serum was carefully transferred into a FINNTIP® 300 tube and stored at 
-20 °C until use. 
Reagents: 
Ketamin Inresa Inresa, Freiburg, D 
2% Rompun Bayer Health Care, Leverkusen, D 
Materials:  
FINNTIP® 300 Thermo Scientific, Vantaa, F 
Centrifuge Megafuge 1.0R Heraeus, Osterode, D 
2.6 Bronchoalveolar lavage (BAL) 
The bronchoalveolar lavage (BAL) was used for the acquisition of cellular and 
protein components from the pulmonary airways. 
2.6.1 Acquisition of BAL from animal experiments 
After the mouse was sacrificed by injection of 5х anesthetics i.p, the trachea was 
dissected and cut into a small hole. Through the hole, a 1.3-mm-diameter venous 
catheter was inserted into the trachea and the lung was lavaged three times by 1 ml PBS 
with protease inhibitor. The cell suspension was centrifuged at 1200 rpm, 4 °C for 10 
minutes and the cell-free supernatant was taken and stored at -20°C until further 
analysis. The cell pellet was resuspended with 1 ml 1% BSA in PBS and the number of 
total cells (leukocytes) was counted. 
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Reagents: 
Ketamin Inresa Inresa, Freiburg, D 
2% Rompun Bayer Health Care, Leverkusen, D 
PBS (Dulbecco´s Phosphate Buffered Saline) PAA Laboratoires GmbH, Pasching, A 
Protease Inhibitor Cocktail Roche, Mannheim, D 
BSA, Fraction V Roth, Karlsruhe, D 
Materials:  
Vasofix Venous Catheter Braun, Melsungen, D 
1 ml Syringe BD, Madrid, S 
Centrifuge Megafuge 1.0R Heraeus, Osterode, D 
2.6.2 Cell count and cell differentiation in the BAL 
The total number of leukocytes was determined by using a CASY® TT cell counter. 
50 µl volume was taken from each sample and made 1:200 dilution by CASY® Ton 
solution for cell counting. Before making cell differentiation, cells were adjusted to a 
concentration of 1×105/mL for cytospin preparations, and two cytospins were made for 
each sample by the following steps: 200 µl cell suspension was added into a sample 
chamber for one cytospin, centrifuged on Cytocentrifuge Cytospin 3 for 5 minutes at 
700 rpm and the cells are centrifuged onto a microscope slide. The cytospins were 
air-dried at room temperature for 1 hour before they were stained with Diff-Quick 
solutions. The cell differentiation was carried out under light microscope at 400х 
magnification by using morphological criteria. In each slide, 100 leukocytes were 
counted for the differentiation of macrophages, eosinophils, neutrophils and 
lymphocytes. The absolute count of each cell, for example, eosinophil count was 
achieved by multiplying the total number of leukocytes with percentage of eosinophils.  
Reagents: 
CASY® Ton Schärfe Systems, Reutlingen, D 
Diff-Quick Dade Behring, Eschborn, Germany 
Materials:  
CASY® Model TT (Cell-Counter) Schärfe Systems, Reutlingen, D 
Sample Chamber Thermo Electron Corporation, USA 
Cytocentrifuge Cytospin 3 GraphPad Software, La Jolla (CA), USA 
Microscope Slides Menzel GmbH, Braunschweig, D 
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Microscope (BH2)  Olympus, Hamburg, D 
2.7 Lymphocyte restimulation 
Lymphocyte restimulation was employed to assess immunological status of the 
body. To perform lymphocyte restimulation, lymph nodes were collected from animal 
experiments and pressed through cell strainers. The resulting cell suspension was 
restimulated with HDM extract in vitro. 
2.7.1 Acquisition of lymph nodes from animal experiments 
After the mice were sacrificed by injection of 5х anesthetics i.p, mediastinal lymph 
nodes were collected and put into ice-cold sterile medium (RPMI 1640+ 10% FCS+ 1% 
L-Glutamine + 1% Antibiotic/Antimycotic). The lymph nodes were pressed through a 
100-µm-diameter cell strainer. The resulting cell suspension was poured into a 15 ml 
tube and filled with medium to a final volume of 5 ml. The tube was placed on ice until 
further processing. 
Reagents: 
RPMI 1640 Schärfe Systems, Reutlingen, D 
FCS Gold PAA Laboratoires GmbH, Pasching, A 
L-Glutamine PAA Laboratoires GmbH, Pasching, A 
Antibiotic/ Antimycotic PAA Laboratoires GmbH, Pasching, A 
Materials:  
Cell Strainer BD Falcon, Bedford, USA 
15ml Tube Sarstedt, Nümbrecht, D 
HERA safe Heraeus, Osterode, D 
2.7.2 In vitro restimulation of lymphocytes with HDM extract 
The cell suspension from 2.7.1 was centrifuged at 1200 rpm for 10 minutes. The 
supernatant was removed and the cell pellet was gently agitated. 5 µl volume was taken 
from each sample and made 1:2000 dilution by CASY® Ton solution for cell counting. 
To get a cell concentration of 2×106/ml, different volume of medium was added to each 
sample according to the cell counts. 200 µl cell suspension from each sample was added 
into the well of 96 Well cell culture plate and stimulated with 50 µg/mL HDM extract. 
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To act as negative control, another 200 µl cell suspension was added into the well 
without HDM stimulation. After incubating at a condition of 37 °C and 5% CO2 for 72 
hours, the plate was centrifuged at 1200 rpm, 4 °C for 10 minutes. Cell-free supernatant 
was carefully transferred and stored at -20 °C until subsequent analysis.  
Reagents: 
RPMI 1640 Schärfe Systems, Reutlingen, D 
FCS Gold PAA Laboratoires GmbH, Pasching, A 
L-Glutamine PAA Laboratoires GmbH, Pasching, A 
Antibiotic/ Antimycotic PAA Laboratoires GmbH, Pasching, A 
Materials:  
Centrifuge Megafuge 1.0R Heraeus, Osterode, D 
96 Well Cell Culture Plate Cellstar, D 
HERA cell 240 Heraeus, Osterode, D 
HERA safe Heraeus, Osterode, D 
2.8 Lung histology 
Lung histology provided morphological changes in the lung. To observe lung 
histology, lung perfusion, acquisition and histological staining and analysis were 
performed.  
2.8.1 Lung perfusion 
To avoid possible interference of red blood cells in the following examinations, 
such as RNA isolation and histological staining, lung perfusion was performed during 
animal preparation. The mouse was sacrificed by administration of 5х anesthetics. Chest 
cavity was opened and the trachea, the lung and the heart were detached. After 
acquisition of the BAL, the venous catheter was left in the trachea. The arteries were 
then severed, a 1.3 mm catheter needle was inserted into the right atrium and at least 3 
ml PBS was injected slowly through the heart and into the lung, taking red blood cells 
out of the severed arteries until the lung turned white.    
Reagents: 
PBS Dulbecco Biochrom AG, Berlin, D 
Materials:  
Materials and methods 
Page 20 
Catheter needle Braun, Melsungen, D 
2.8.2 Acquisition of lung tissue from animal experiments 
After perfusion, the right lung was tied off at the main-stem bronchus, cut out and 
put into liquid nitrogen for RNA isolation. The left lung was tied off at the trachea after 
injection of 1 ml cold formalin through the trachea catheter, then cut out and fixed in 
6% paraformaldehyde via the trachea for 24 hours.    
Reagents: 
Paraformaldehyde Merck, Darmstadt, D 
Materials:  
Micro-crew Tube 2 ml Sarstedt, Nümbrecht, D 
2.8.3 Histological staining for the lung 
The fixed left lung was taken out of the paraformaldehyde, embedded in 2% 
agarose and cut into 2 mm segments. All the segments were put on one layer, filled with 
2% agar and embedded with paraffin. 5 µm sections were cut from the paraffin blocks 
by using Rotary Microtome and loaded onto microscope slides.  
Each slide was set to dry in a 60 °C incubator overnight and then deparaffinized 
through xylene, rehydrated in descending alcohol series (100%, 96% and 70%), and 
rinsed in distilled water before histological staining was performed. 
Periodic acid-Schiff (PAS) was used for demonstration of mucus production and 
goblet cell hyperplasia in the airways. The deparaffinzed slide was immersed in periodic 
acid, which selectively oxidized glucose residues to aldehydes. After rinsing, the slide 
was immersed in Schiff's reagent, which was bound by aldehydes and a magenta-color 
reaction was created. Because mucus is a glycoprotein produced by goblet cells, they 
are stained purple-magenta in PAS staining. The slide was dipped into Hematoxylin 
solution acc. to Gill III for a counterstain followed by a thorough rinsing in water. The 
slide was dehydrated in ascending alcohol series (70%, 96% and 100%), fixed in xylene 
and covered with Vectormount.  
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Reagents: 
Agar Merck, Darmstadt, D  
Paraffin Merck, Darmstadt, D 
Ethanol Sigma-Aldrich Chemie GmbH, Steinheim,D 
Periodic acid Merck, Darmstadt, D 
Hematoxylin solution acc. to Gill III Roth, Karlsruhe, D 
Schiff’s reagent Roth, Karlsruhe, D 
Materials:  
Rotary Microtome Microm GmbH, Walldorf, D 
Microscope Slides Menzel GmbH, Braunschweig, D 
Mounting Medium Vector Laboratories, Inc. Burlingame, CA 
Incubator Heraeus, Osterode, D 
2.8.4 Analysis of histological changes in the lung 
Histological observations were carried out under a PC-based Olympus light 
microscope BX51 equipped with a CAST-Grid system. All sections were delineated (at 
a magnification of 25х) and the fields of view to be analysed (at a magnification of 400х) 
were automatically defined according to systemic uniform random sampling. Around 
150 fragments were selected per lung section. 
In PAS-stained lung sections, goblet cells and epithelial cells which were crossed 
by basement membrane and the mucus which hit the test points were counted. The 
percentage of goblet cells (%) and the volume of GC-mucus content (µm) were 
calculated according to the following formula (from lab SOP document):  
 
 
 
where PGC is percentage of goblet cells, NGC the number of goblet cells, NEC the number 
of epithelial cells, VMucus the volume of GC-mucus content, NMucus the number of 
GC-mucus content, and L(P) is the length per test point. 
Materials:  
Microscope Slides Menzel GmbH, Braunschweig, D 
Microscope (BX51) Olympus, Hamburg, D 
CAST Visiopharm, DK 
= 
NGC·100  
= PGC (%) 
NGC+ NEC  
NMucus·L(P)·0.5   
VMucus (µm) 
NGC+ NEC  
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2.9 Enzyme-linked immunosorbent assay (ELISA) 
ELISA served to quantitate the presence of antigens or antibodies in the samples. 
The basic principle of ELISA is to use an enzyme to detect the binding of unknown 
antigens (or antibodies) to known antibodies (or antigens). To detect antigen A, purified 
first antibody binds to the surface of microtiter plate. Unspecific bindings are blocked 
by adding irrelevant proteins. The samples were coated onto the surface of the wells. 
Antigen A from the samples bound to the first antibody. Unbound substances were 
washed away. After the adding of the biotinylated second antibody immunocomplex 
was formed. This was recognized by HRP (Horseradish Peroxidase) and therefore 
became Streptavidin-Peroxidase-Complex. The addition of substrate will cause a color 
reaction and the optical density was immediately determined by using a 
microtiter-plates-reader in which the absorption wavelength is set to 450 nm. 
2.9.1 ELISA for cytokines and chemokines in the BAL fluid (BALF) 
The ELISA procedure for cytokine IL-5 was detailed as the following: 
The primary antibody for IL-5 was diluted with 0.1 M NaHCO3 solution (pH=8.3) 
to get a concentration of 1 µg/mL. A 96-well-microtiterplate was coated with 50 µl/well 
diluted primary antibody, and incubated at 4°C overnight. The solution was discarded 
and the plate was washed with washing buffer (PBS with 0.1% Tween 20) for four times. 
Free binding sites were saturated by incubating the plate with 100 µl/well blocking 
buffer (PBS with 1% BSA) at room temperature for 2 hours. After washing, a series of 
2-fold diluted standards (the highest standard is 4000 pg/mL), blanks and samples were 
added to the plate and incubated on the shaker at room temperature for 2 hours. The 
plate was washed four times and 50 µl detection antibody was applied to each well with 
a concentration of 2 µg/mL. The plate was placed on a shaker and incubated for 2 hours 
at room temperature. After another four-time washing step, the streptavidin-peroxidase 
was 1:1000 diluted and added into the plate, followed by 30 minutes’ incubation at 
room temperature in the dark. After a final eight-time washing, the plate was applied 
with 100 µl/well peroxidase substrate solution and incubated in the dark for about 15 
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minutes’ color reaction. The addition of 50 µl stop solution (2 M H2SO4) into each well 
caused the color changed from blue to yellow, which was measured by a 
microtiter-plates-reader with the absorption wavelength set to 450 nm. The data analysis 
was carried out by using Software Megallan 5. A standard curve was generated to verify 
analysis linearity and the concentration of IL-5 was calculated and expressed as pg/mL.                   
The detections of IFN-γ, IL-10, IL-17, CXCL1, CXCL2, and CCL11 (eotaxin) in 
the BAL followed the same procedure as described above, but with different 
concentrations of antibodies and standards (see Table 2.1). 
Table 2.1 Concentrations of antibodies and standards for the cytokine- and chemokine-ELISA 
Item Primary Antibody Detection Antibody 1st Standard 
IL-5 1 µg/mL 2 µg/mL 4000 pg/mL 
IFN-γ 3 µg/mL 1 µg/mL 10,000 pg/mL 
IL-10 1:250 diluted 1 µg/mL 4000 pg/mL 
IL-17 2 µg/mL 400 ng/mL 1000 pg/mL 
CXCL1 2 µg/mL 200 ng/mL 1000 pg/mL 
CXCL2 2 µg/mL 75 ng/mL 1000 pg/mL 
Eotaxin 0.8 µg/mL 200 ng/mL 500 pg/mL 
    
Reagents 
Purified rat anti-mouse/human IL5 BD Pharmingen, San Diego, USA 
Biotinylated rat anti-mouse IL-5 BD Pharmingen, San Diego, USA 
Purified rat anti-mouse IFN-γ BD Pharmingen, San Diego, USA 
Biotinylated anti-mouse IFN-γ BD Pharmingen, San Diego, USA 
BD OptEIATM Set Mouse IL-10 BD Pharmingen, San Diego, USA 
Mouse IL-17 R&D Systems, Minneapolis, USA 
Mouse CXCL1/KC R&D Systems, Minneapolis, USA 
Mouse CXCL2/MIP2 R&D Systems, Minneapolis, USA 
Mouse CCL11 (eotaxin) R&D Systems, Minneapolis, USA 
PBS (Dulbecco´s Phosphate-buffered Saline) Biochrom AG, Berlin, D 
BSA, Fraction V Roth, Karlsruhe, D 
Tween 20 Roth, Karlsruhe, D 
Streptavidin/Peroxidase Sigma, Taufkirchen, D 
BM Blue POD Substrate Roche, Mannheim, D 
NaHCO3 Merck, Darmstadt, D 
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H2SO4 Merck, Darmstadt, D 
Materials: 
96-Well-Microtiterplate  Nunc, Wiesbaden, D 
Nunc-ImmunoTM Wash 12 Nunc, Wiesbaden, D 
Microtiter-plates-reader Sunrise Tecan, Crailsheim, D 
Magellan 5 Tecan, Crailsheim, D 
2.9.2 ELISA for immunoglobulins in the blood serum 
The level of HDM-specific IgE (HDM-IgE) in the blood serum was determined by 
the following steps: 
HDM extract was diluted to 50 µg/mL in 0.1 M NaHCO3 solution (pH=8.3). A 
96-well-microtiterplate was coated with 50 µl/well diluted HDM solution, and 
incubated at 4 °C overnight. The solution was discarded and the plate was washed with 
washing buffer for four times. Free binding sites were saturated by incubating the plate 
with 100 µl/well blocking buffer at room temperature for 2 hours. After washing, blood 
samples were 1:10 diluted in washing buffer and added to the plate and incubated on the 
shaker at room temperature for 2 hours. The plate was washed four times and 50 µl 
detection antibody was applied to each well with a concentration of 2.5 µg/mL. The 
plate was placed on a shaker and incubated for 2 hours at room temperature. After 
another four-time washing, the streptavidin-peroxidase was 1:1000 diluted and added 
into the plate, followed by 30 minutes’ incubation at room temperature in the dark. 
After a final eight-time washing, the plate was applied with 100 µl/well peroxidase 
substrate solution and incubated in the dark for about 15 minutes’ color reaction. The 
addition of 50 µl stop solution (2 M H2SO4) into each well led to a color change from 
blue to yellow, which was measured by a microtiter-plates-reader with the absorption 
wavelength set to 450 nm. The data analysis was carried out by using Software 
Megallan 5. The value of HDM-specific IgE was expressed as OD450 (Abs-Blank), in 
which Abs stands for absorption. 
The same procedures were applied to the detections of HDM-specific IgG1 
(HDM-IgG1), HDM-specific IgG2a (HDM-IgG2a), but the concentrations of antibodies 
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for each item differed (see Table 2.2). The measurement of total IgE followed a similar 
procedure but with known concentrations of primary antibody, detection antibody and 
standards from which a standard curve was formed and the concentration of total IgE 
was calculated and expressed as ng/mL. 
Table 2.2 Concentrations of antibodies for immunoglobulin-ELISA 
Item Primary Antibody Detection Antibody 1st Standard Sample Dilution 
factor HDM-specific IgG1 / 2.5 µg/mL / 1:100 
HDM-specific IgG2a / 2.5 µg/mL / 1:100 
HDM-specific IgE / 2.5 µg/mL / 1:10 
Total IgE 10.6 µg/mL 2.5 µg/mL 250 ng/mL 1:10 
 
Reagents 
HDM (Lot no. W0657678) Allergo Pharmaco, D 
Anti-mouse IgG1 biotinylated BD Pharmingen, San Diego, USA 
Anti-mouse IgE biotinylated BD Pharmingen, San Diego, USA 
Anti-mouse IgG2a biotinylated BD Pharmingen, San Diego, USA 
PBS (Dulbecco´s Phosphate-buffered Saline) Biochrom AG, Berlin, D 
BSA, Fraction V Roth, Karlsruhe, D 
Tween 20 Roth, Karlsruhe, D 
Streptavidin/Peroxidase Sigma, Taufkirchen, D 
BM Blue POD Substrate Roche, Mannheim, D 
NaHCO3 Merck, Darmstadt, D 
H2SO4 Merck, Darmstadt, D 
Materials: 
96-Well-Microtiterplate  Nunc, Wiesbaden, D 
Nunc-ImmunoTM Wash 12 Nunc, Wiesbaden, D 
Microtiter plates reader Sunrise Tecan, Crailsheim, D 
Analysis software Magellan Tecan, Crailsheim, D 
2.10 Cytometric Bead Array (CBA) 
The CBA is a bead based immunoassay for the simultaneous determination of 
different cytokines in one single sample. It combines the principles of sandwich 
immunoassays with the fluorescence detection ability of flow cytometry. Briefly, the 
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capture beads which are coated with specific capture antibodies are mixed with a 
sample or standard and then mixed with phycoerythrin (PE) conjugated detection 
antibodies to form sandwich complexes. After incubation and subsequent washing, the 
samples are acquired by a flow cytometry and the data are transformed to graphical and 
tabular formats by FCAP ArrayTM Software. 
A cytokine kit of FlowCytomix Mouse Th1/Th2 8 plex from Bender MedSystem 
was used for the detection of IL-4, IL-5, IL-13, IFN-γ, IL-10, IL-17A, IL-9, GM-CSF, 
in the supernatants of in vitro restimulated lymphocytes. A volume of 25 µl is required 
for each sample.  
Reagents: 
FlowCytomix Mouse Th1/Th2 8 plex Bender MedSystems, Wien, A 
Materials:  
BD FACSArray™ BD, Heidelberg, D 
FCAP ArrayTM Software BD, Heidelberg, D 
2.11 Analysis of gene expression at mRNA level 
Quantitative real time polymerase chain reaction (QPCR) was employed to quantify 
gene expression in mRNA level. To carry out QPCR, RNA isolation and quantification, 
DNA digestion and reverse transcription were performed.  
2.11.1 RNA isolation 
The isolation of RNA from lung homogenates was performed by using a 
combination of reagents from TriFast and RNeasy Mini kit. First, 50~100 mg tissue was 
taken from the lung and put into liquid nitrogen. After nitrogen vaporized, the tissue 
was disrupted and homogenized into powder by a pestle followed by the adding of 1 ml 
TriFast reagent. The reagent contains phenol and guanidine in a single phase solution. 
The addition of chloroform and subsequent centrifugation separate the homogenate into 
three phases, with RNA in the colorless upper phase. 350 µl RNA solution was carefully 
transferred into RNeasy Mini column together with the same volume of 70% ethanol. In 
the column, RNA was selectively bound to a silica-gel membrane and contaminants 
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were efficiently washed away by RNeasy buffers. High-quality RNA was then eluted in 
30 µl RNase-free water and stored in 1.5 ml Eppendorf tube at -80 °C until further use.    
Reagents:  
peqGOLD TriFast Peqlab, Erlangen, D 
RNeasy Mini kit Qiagen, Hilden, D 
Chloroform Roth, Karlsruhe, D 
Ethanol absolute Sigma-Aldrich Chemie GmbH, Steinheim,D 
RNase free water Eppendorf, Hamburg, D 
Materials:  
BIOFUGE pico Heraeus, Osterode, D 
1.5ml Eppendorf Tube Eppendorf, Hamburg, D 
2.11.2 RNA quantification 
The determination of RNA concentration was carried out by using a 
Spectrophotometer. 2 µl volume was taken from each sample and made 1:50 dilution by 
RNase-free water. RNA content was determined by measuring absorpance at 260 nm. 
The ratio of 260/280 was obtained by simultaneous measurement at 280 nm, followed 
by the statement about the quality of RNA preparation. In good preparations, this ratio 
ranges from 1.8 to 2.0.   
Reagents:  
RNase free water Eppendorf, Hamburg, D 
Materials:  
Ultrospec 3100 pro UV/Visible Spectrophotometer Biochrom, Cambridge, UK 
2.11.3 DNA digestion 
DNA digestion was performed to remove the contaminating DNA from the RNA 
preparations, by using the enzyme deoxyribonuclease I (DNase I). After acquiring a 
solution of 0.5 µg RNA in 8 µl H2O, 1.2 µl 10х DNase Buffer, 1 µl DNase I and 1.2 µl 
H2O were added into the solution to make a volume of 12 µl, and incubated at room 
temperature for 15 minutes. The reaction of DNA degradation was stopped by the 
addition of 1 µl 25 mM EDTA. DNase I was inactivated by ten minutes’ incubation at 
65 °C. The DNA-free RNA was then stored at -80 °C until further use. 
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Reagents:  
Deoxyribonuclease I, Amplification Grade Invitrogen, Carlsbad, CA, USA 
Materials:  
Thermocell Cooling & Heating Block Biozym, Hessisch Oldendorf, D 
2.11.4 Reverse transcription 
In the process of reverse transcription, the purified mRNA was transcribed into 
complementary DNA (cDNA) by using reverse transcriptase. The reaction system 
includes 0.5 µg RNA, 2 µl 10x RT buffer, 2 µl dNTP mix (final concentration: 0.5 mM 
of each dNTP), 1 µl oligo-dT 18 primer (final concentration: 1 µM) and 1 µl Omniscript 
reverse transcriptase, with an end volume of 20 µl filled with RNase-free water. The 
reaction condition is one hour’s incubation at 37 °C followed by denaturing at 93 °C for 
5 minutes. The resulting cDNA was diluted 1:2 with RNase-free water and stored at -20 
°C until subsequent analysis. 
Reagents: 
Omniscript® Reverse Transcription Kit Qiagen, Hilden, D 
Oligo-dT 18 Primer Metabion, Martinsried, D 
Materials:  
MJ MiniTM Personal Thermal Cycler Bio-Rad, Singapore 
2.11.5 Quantitative real time Polymerase Chain Reaction (QPCR) 
The principle of QPCR is based on real-time detection of fluorescent signals from 
amplified DNA. The machine (RotorGene™ 3000) used for this detection consists of 
PCR device and fluorescence detector. PCR amplification was performed by using 
QuantiTect SYBR Green PCR kit, which contains a TaqPolymerase from MasterMix, 
dNTPs, PCR buffer and the fluorescent dye SybrGreen I. SybrGreen I intercalated into 
the double-stranded DNA (dsDNA) and gave a fluorescent signal which is received by 
the detector. During the extension phase, more and more SybrGreen I bound to the 
newly synthesized dsDNA, and by this way the increase of PCR products were 
monitored real-time. After 45 cycles, melting curve analysis was performed to verify 
PCR products. Because every dsDNA had a unique melting temperature (Tm), a 
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temperature at which half of the DNA helical structure is lost, and a narrow melting 
peak, one can judge from the melting curve if any unspecific products were produced 
during amplification. 
The reaction system includes 5 µl SybrGreen mix, 0.25 µl forward primer (10 
pmol/µl), 0.25 µl reverse primer (10 pmol/µl) and 2.5 µl RNase-free water. The reaction 
condition was listed in Table 2.3, and the annealing temperature was adjusted for 
optimal amplification in each reaction. 
To determine the difference at mRNA expression level, targeted genes were 
amplified simultaneously with the house keeping gene L32 or β-actin. The targeted 
genes included TNFα, TLR4, GM-CSF, CCL17, IL-4, IL-5, IL-13, IFNγ, IL-10, IL-17A, 
CXCL1, CXCL2, CCL11 (eotaxin), GATA-3, Tbx21, Foxp3, Rorγt. Calculation of 
relative changes in the targeted genes was performed against L32 or β-actin by using the 
∆CT method (Zasłona et al., 2009). Primer sequences are detailed in Table 2.4. 
Table 2.3 Reaction conditions for QPCR 
PCR amplification 
Pre-denaturing 15 minutes 95 °C  
Denaturing 15 seconds 94 °C 
45 Cycles Annealing 30 seconds 55 °C  
Extension 15 seconds 72 °C 
Melting curve analysis 
Temperature gradient from 65 °C to 95 °C with an interval of 0.1 °C 
 
Table 2.4 (to be continued) Primers for QPCR 
Gene Name  Sequence (5’-3’) 
TNF-α 
sense AgC CCA CgT CgT AgC AAA CC 
antisense TAC AAC CCA TCg gCT ggC AC 
TLR4 
sense gCA ggT ggA ATT gTA TCg CC 
antisense TTC gAg gCT TTT CCA TCC AA 
GM-CSF 
sense ATg CCT gTC ACg TTg AAT gA 
antisense CCg TAg ACC CTg CTC gAA TA 
CCL17 
sense AAT gTA ggC CgA gAg TgC Tg 
antisense CAT CCC Tgg AAC ACT CCA CT 
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Table 2.4 (continued) Primers for QPCR 
Gene Name  Sequence (5’-3’) 
IL-4 
sense TCA ACC CCC AgC Tag TTg TC 
antisense TgT TCT TCg TTg CTg TgA gg 
IL-5 
sense CTg TCC TCg CCA CAC TTC 
antisense ACg ATg Agg CTT CCT gTC 
IL-13 
sense CCA TCC CAT CCC TAC AgA AA 
antisense ATA ggC AgC AAA CCA TgT CC 
IFNγ 
sense gCg TCA TTG AAT CAC ACC Tg 
antisense TgA gCT CAT TgA ATg CTT gg 
IL-10 
 
sense gCA Tgg CCC AgA AAT CAA gg 
antisense TCT TCA CCT gCT CCA CTg CC 
IL-17A 
sense AgC Tgg ACC ACC ACA TgA AT 
antisense AgC ATC TTC TCg ACC CTg AA 
CXCL1 
sense CTT gAA ggT gTT gCC CTC Ag 
antisense Tgg ggA CAC CTT TTA gCA TC 
CXCL2 
sense AAA gTT TgC CTT gAC CCT gA 
antisense Agg CAC ATC AggG TAC gAT CC 
CCL11 (eotaxin) 
sense CCA Agg ACT Tgg CTT CAT gT 
antisense AAC TCg TCC CAT TgT gTT CC 
GATA-3 
sense gTC ATC CCT gAg CCA CAT CT 
antisense Agg gCT CTg CCT CTC TAA CC 
Tbx21 
sense Agg TgT CTg ggA AgC TgA gA 
antisense CCA CAT CCA CAA ACA TCC Tg 
Foxp3 
sense TCC AAT CCC TgC CCT TgA CC 
antisense CAC ATC ATC gCC Cgg TTT CC 
Rorγt 
sense ATA gCA CTg ACg gCC AAC TT 
antisense AgA AAC Tgg gAA TgC AgT 
L32 
sense gCA AgT TCC Tgg TCC ACA AT 
antisense ggg ATT ggT gAC TCT gAT gg 
β-actin 
sense TgT TAC CAA CTg ggA CgA CA 
antisense ggg gTg TTg AAg gTC TCA AA  
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Reagents: 
QuantiTectTM SybrGreen PCR Master Mix Qiagen, Hilden, D 
Primers Metabion, Martinsried, D 
Materials:  
RotorGene™ Software Corbett, Sydney, AUS 
0.1 mL Strip-Tubes Corbett, Sydney, AUS 
RotorGene™ 3000 Corbett, Sydney, AUS 
2.12 Statistical analysis 
These data are representative of experiments with 4-6 mice in each group. All data 
are expressed as mean ± standard error (SEM) and analyzed for significance using 
Student’s unpaired t-test or one-way ANOVA. Student’s unpaired t-test was used to 
compare the difference between two groups and calculate the probability value. To 
compare more than two groups, one-way ANOVA was conducted. A probability value of 
less than 0.05 (p < 0.05) was considered to indicate statistical significance. Data 
analysis was performed by using the software GraphPad Prism 5. 
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3 Results 
3.1 Comparison of different origins of house dust mite extracts in a mouse model 
In the first experiment, three different commercial HDM extracts (provided by 
Allergopharma Co. and Greer Labs, respectively), namely HDM1, HDM2, and HDM3 
were compared in regards to inducing an asthma phenotype. HDM extracts are 
complicated mixtures of proteins and peptides, among which Der p 1 and Der p 2 are 
regarded as the major allergens. One difference between the three used extracts is the 
content of Der p 1. For example, in HDM1 which was provided by Allergopharma Co., 
Der p 1 (4.5 µg) constitutes 4.5% of the whole extract weight (100 µg), while in Greer 
Labs-origined HDM2, Der p 1 constitutes 1.4% of 100 µg extract. The concentrations 
of Der p 1, Der p 2 and total protein in the three extracts are summarized in Table 3.1. 
According to sensitization protocol 1 (Figure 2.1), the whole HDM extracts were 
applied intranasally to the mice once a week for six times, each time at a dose of 100 
µg. 
Table 3.1 A brief data sheet of HDM extracts 
Name Company Batch No. Der p 1 content Der p 2 content Protein content 
HDM1 Allergopharma  W9001009 4.49 µg/100 µg 
HM 
2.35 µg/100 µg 29 µg/100 µg 
HDM HDM2 Greer Labs 125118 1.4 µg/100 µg 
HDM 
unknown 27 µg/100 µg 
HDM HDM3 Greer Labs 140153 1.3 µg/100 µg 
HDM 
unknown 23 µg/100 µg 
HDM 
3.1.1 AHR and airway inflammation induced by different origins of HDM 
extracts 
As shown in Figure 3.1, administration of the three HDM extracts didn’t affect 
airway reactivity of the lung (A), but had different influences on the recruitments of 
inflammatory cells into the airways (B). In comparison to control mice (PBS-treated 
mice), HDM1-immunized mice displayed a prominent airway inflammation which was 
due to an increase in the number of neutrophils, eosinophils and lymphocytes. In 
HDM2-immunized mice, the number of total leukocytes and neutrophils were 
significantly higher, eosinophils and lymphocytes remained comparable, and 
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macrophages were significantly lower, as compared to PBS-mice. In contrast, 
sensitization of the mice with HDM3 only promoted a weak inflammatory response.  
A strong airway inflammation was observed in both HDM1- and 
HDM2-immunized mice, but the inflammatory types varied. In HDM1-mice, 
neutrophils and eosinophils were the predominant infiltrating cells, while in 
HDM2-mice, a more robust neutrophil influx was induced into the airway, which was 
not accompanied by eosinophil inflammation. 
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Figure 3.1 Comparison of BAL cell types in a murine model sensitized by different origins of HDM 
extracts 
 
 
 
 
 
3.1.2 Cytokines and chemokines in the BAL fluid 
Cellular airway inflammation was closely related to dysfunctions in Th2 
proinflammatory cytokines (Busse et al., 2001) or chemokines. Therefore, various 
cytokines and chemokines in the BAL fluid were determined. As demonstrated in Figure 
BALB/c mice (n = 5 per group) were instilled intranasally with 100 µg HDM extracts once a week 
for 6 times. (A) 24 hours after the last instillation, aiway reactivity was measured by Head-out body 
plethysmography. (B) 48 hours after the last instillation, cell differentiation of leukocytes in the 
BAL fluid was performed. *p < 0.05, **p < 0.01 
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3.2, the protein levels of CXCL1 were significantly elevated in mice when sensitized by 
the three HDM extracts, as compared to PBS-mice. Meanwhile, the chemokine CXCL2 
and the cytokines IL-5, IFNγ and IL-17 were undetectable in all mice. 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2 Comparison of BAL CXCL1 in a murine model sensitized by different origins of HDM 
extracts 
 
 
 
 
3.1.3 Immunoglobulins in the blood serum 
The production of total IgE in the blood serum was not affected by the 
sensitizations of the three HDM extracts (see Figure 3.3). 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3 Comparison of total IgE in a murine model sensitized by different origins of HDM 
extracts 
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BALB/c mice (n = 5 per group) were instilled intranasally with 100µg HDM extracts once a week for 
6 times. 48 hours after the last instillation, the level of total IgE in the blood serum was examined by 
ELISA. 
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BALB/c mice (n = 5 per group) were instilled intranasally with 100 µg HDM extracts once a week for 
6 times. 48 hours after the last instillation, the protein level of chemokine CXCL1 in the BAL fluid 
was examined by ELISA. **p < 0.01 
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3.1.4 Histological observations in the lung tissue 
Histological examination remains the “gold standard” for assessing asthmatic 
airway remodeling such as goblet cell hyperplasia (GCH) and mucus hypersecretion. As 
depicted in Figure 3.4, in mice sensitized by the three HDM extracts, the percentage of 
goblet cells were markedly increased. The volume of mucus content was concurrently 
increased without reaching statistical difference.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4 Comparison of histological observations in a murine model sensitized by different origins 
of HDM extracts 
 
 
 
 
 
BALB/c mice (n = 5 per group) were instilled intranasally with 100 µg HDM extracts once a week 
for 6 times. 48 hours after the last instillation, the lungs were cut into 5 µm sections and subjected 
to PAS staining. (A) Representative photomicrographs of PAS-stained lung sections. (B) Proportion 
of goblet cells and the volume of mucus content were determined by using the software CAST.     
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3.2 Comparison of different doses of HDM extracts in the induction of asthma 
phenotype in BALB/c mice 
It is known that the dose of the sensitizing allergen is a critical determinant for 
inducing an asthma phenotype in the murine OVA models. Could a lower dose of HDM 
extract still elicit an airway inflammation dominated by neutrophils and eosinophils as 
described above? To address this question, the mice were sensitized with different doses 
of HDM1 (10 µg, 50 µg and 100 µg), according to sensitization protocol 1. After six 
times of sensitization once a week, the mice were sacrificed and asthma-associated 
parameters were analyzed. Initial experiment demonstrated that 10 µg HDM1 did not 
induce an asthmatic response in the mouse model (data not shown). In this experiment, 
dose effect of HDM1 was determined by comparing various parameters between 50 µg 
and 100 µg HDM1-treated mice. The extract HDM1 was provided by Allergopharma Co. 
(see Table 3.2). 
Table 3.2 A brief data sheet of HDM1 
Name Company Batch No. Der p 1 content Der p 2 content Protein content 
HDM1 Allergopharma  W0657678 4.49 µg/100 µg 
HDM 
2.35 µg/100 µg 29 µg/100 µg 
HDM 
3.2.1 AHR and airway inflammation elicited by different doses of HDM extrats 
Compared with the PBS group, neither application of the mice with 50 µg or 100 µg 
HDM1 significantly changed airway reactivity of the lung (see Figure 3.5 (A)). 
However, as shown in Figure 3.5 (B), an inflammatory response of the airway was 
elicited by the instillation of HDM1, which was mainly due to a rise in the number of 
neutrophils and eosinophils. The lymphocytes increased slightly, without reaching a 
statistical difference. This response was more pronounced in mice sensitized by 100 µg 
HDM1 than in mice sensitized by 50 µg HDM1. 
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Figure 3.5 Comparison of BAL cell types in a murine model sensitized by different doses of HDM1 
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(A) 
BALB/c mice (n = 6 per group) were instilled intranasally with 50 µg or 100 µg HDM1 once a week for 
6 times. (A) 24 hours after the last instillation of HDM1, aiway reactivity was measured by Head-out 
body plethysmography. (B) 48 hours after the last instillation of HDM1, cell differentiation of 
leukocytes in the BAL fluid was performed. *p < 0.05, **p < 0.01 
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3.2.2 Cytokines and chemokines in the BAL fluid 
Different doses of HDM1 resulted in different concentrations of cytokines and 
chemokines in the BAL fluid. As shown in Figure 3.6, in mice sensitized by 100 µg 
HDM1 the protein levels of CXCL1 and IL-5 were substantially elevated. In mice 
sensitized by 50 µg HDM1, the level of CXCL1 was substantially elevated as well, 
whereas the level of IL-5 was subtly increased, without reaching statistical difference. 
The levels of the chemokine CXCL2 and the cytokines IFNγ and IL-17 were 
undetectable in all mice. 
             
 
 
Figure 3.6 Comparison of BAL CXCL1 and IL-5 in a murine model sensitized by different doses of 
HDM1 
 
 
 
 
3.2.3 Immunoglobulins in the serum 
As shown in Figure 3.7, in mice sensitized by 100 µg HDM1, the level of 
HDM-IgG1 was markedly increased, the level of HDM-IgG2a was moderately 
increased (p = 0.067), and the level of total IgE remained comparable to that of 
PBS-mice. In mice sensitized by 50 µg HDM1, the level of HDM-IgG1 was 
significantly increased as well, the level of HDM-IgG2a was not altered, while the level 
of total IgE was elevated, almost statistically differently (p = 0.063). In contrast, the 
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BALB/c mice (n = 6 per group) were instilled intranasally with 50 µg or 100 µg HDM1 once a week for 
6 times. 48 hours after the last instillation, protein levels of CXCL1 and IL-5 in the BAL fluid were 
examined by ELISA. *p < 0.05, **p < 0.01 
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amount of HDM-IgE was undetectable in all groups. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.7 Comparison of immunoglobulins in a murine model sensitized by different doses of 
HDM1 
 
 
 
 
3.2.4 Histological manifestations in the lung tissue 
As depicted in Figure 3.8, administration of 50 µg or 100 µg HDM1 elicited a 
substantial increase in the proportion of goblet cells and the volume of mucus content. 
Between the two HDM groups, there was no apparent difference regarding GCH and 
mucus hypersecretion. 
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BALB/c mice (n = 6 per group) were instilled intranasally with 50 µg or 100 µg HDM1 once a week 
for 6 times. 48 hours after the last instillation, the levels of serum immunoglobulins HDM-IgG1, 
HDM-IgG2a, and total IgE were examined by ELISA. **p < 0.01 
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Figure 3.8 Comparison of histological manifestations in a murine model sensitized by different 
doses of HDM1 
  
 
 
 
 
 
3.2.5 Expression profiling of asthma-related genes in the lung tissue 
To further investigate the underlying mechanism which accounted for the abnormal 
biological events in HDM-induced asthma phenotype, expression profiling of 
asthma-related genes was carried out. First, the expressions of innate immune genes 
such as TNFα, TLR4, GM-CSF and CCL17 were examined. Then, genes which encode 
the cytokines and chemokines IL-4, IL-5, IL-13, IFNγ, IL-10, IL-17, CXCL1, CXCL2 
and CCL11 (eotaxin) were analyzed. Afterwards, transcription factors including 
GATA-3, Tbx21, FOXp3 and Rorγt which regulate T cell balance were quantified.  
BALB/c mice (n = 6 per group) were instilled intranasally with 50 µg or 100 µg HDM1 once a week 
for 6 times. 48 hours after the last instillation, the lungs were cut into 5 µm sections and subjected to 
PAS staining. (A) Representative photomicrographs of PAS-stained lung sections. (B) Proportion of 
goblet cells and the volume of mucus content were determined by using the software CAST.      
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As shown in Figure 3.9 and Figure 3.10, a variety of genes showed aberrant mRNA 
expression in response to HDM1. In mice sensitized by 100 µg HDM1, the expressions 
of TNF-α, CCL17, IL-5, IL-13, IL-10, IL-17A, CXCL1, and CCL11 (eotaxin) were 
markedly upregulated; the expressions of IL-4 (p = 0.105) and TLR4 (p = 0.074) were 
moderately enhanced; the expressions of GM-CSF, IFNγ, CXCL2, GATA3, Tbx21, 
Foxp3 and Rorγt remained unaltered, as compared to PBS-mice. In mice sensitized by 
50 µg HDM1, the expressions of TNF-α, IL-13, IL-10, IL-17A and CCL11 (eotaxin) 
increased significantly, the expressions of IL-4 (p = 0.105) and TLR4 (p = 0.074) were 
moderately enhanced, and the expressions of GM-CSF, CCL17, IL-5, IFNγ, CXCL1, 
CXCL2, GATA3, Tbx21, Foxp3 and Rorγt remained comparable to PBS-mice. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.9 Comparison of mRNA expressions of innate immune genes in a murine model sensitized 
by different doses of HDM1 
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BALB/c mice (n = 6 per group) were instilled intranasally with 50 µg or 100 µg HDM1 once a week 
for 6 times. 48 hours after the last instillation, the lungs were homogenized and mRNA expressions 
of genes TNFα, TLR4, GM-CSF and CCL17 were analyzed by QPCR. *p < 0.05, **p < 0.01 
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Figure 3.10 Comparison of mRNA expressions of cytokines and chemokine genes in a murine model 
sensitized by different doses of HDM1 
 
 
 
 
 
 
 
 
BALB/c mice (n = 6 per group) were instilled intranasally with 50 µg or 100 µg HDM1 once a week for 
6 times. 48 hours after the last instillation, the lungs were homogenized and mRNA expressions of genes 
IL-4, IL-5, IL-13, IL-10, IL-17, CXCL1, CXCL2 and CCL11 (eotaxin) were analyzed by QPCR.     
*
p < 0.05, **p < 0.01 
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3.3 Evaluation of the kinetics of HDM-induced asthmatic response in BALB/c 
mice 
Based on reported data and our previous results, this experiment was designed to 
investigate crucial biological events 24 hours and 48 hours after the last instillation of 
HDM1. The sensitization was carried out according to sensitization protocol 2 (Figure 
2.2). The dose used in this experiment was 100 µg HDM1, which was provided by 
Allergopharma Co. (see Table 3.3).  
Table 3.3 A brief data sheet of HDM1 
Name Company Batch No. Der p 1 content Der p 2 content Protein content 
HDM1 Allergopharma  W0657678 4.49 µg/100 µg 
HDM 
2.35 µg/100 µg 29 µg/100 µg 
HDM 
3.3.1 Kinetics of development of airway inflammation 
It was noticed that inflammatory cells migrated into the airway successively at 
different time points. As depicted in Figure 3.11, 24 hours after the last instillation of 
HDM1, the sensitized mice showed a sharp increase in the number of total leukocytes, 
mostly due to an increase of the neutrophils, while the numbers of lymphcotyes and 
macrophages remained unchanged, as compared to PBS-mice. At this time point, no 
eosinophils appeared in HDM-sensitized mice or PBS-mice. Instead, a rise in 
eosinophils was observed 48 hours after the last instillation. Also at this time point, the 
number of lymphocytes increased significantly, the numbers of total leukocytes and 
neutrophils were still higher, while macrophages remained unaltered, as compared to 
PBS-mice. 
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Figure 3.11 Kinetics of development of airway inflammation in HDM-induced murine asthma 
model 
 
 
 
 
3.3.2 Kinetics of production of BAL cytokines and chemokines 
As shown in Figure 3.12, 24 hours after the last instillation of HDM1, the sensitized 
mice displayed a remarkable increase of protein levels of CXCL1 and IL-5 in the BAL 
fluid, as compared to PBS-mice. 48 hours after the last instillation, the level of 
chemokine CXCL1 remained higher in HDM-sensitized mice than in PBS-mice, while 
the protein level of IL-5 in the sensitized mice returned to a normal level of nearly zero. 
In contrast, the chemokine CCL11 (eotaxin) was not detectable in the BAL fluid at both 
time points in HDM-sensitized and non-sensitized mice. 
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BALB/c mice (n = 5 per group) were instilled intranasally with 100 µg HDM1 once a week for 4 
times. 24 hours and 48 hours after the last instillation of HDM1, the mice were sacrificed, respectively, 
and cell differentiation of leukocytes in the BAL fluid was performed. *p < 0.05, **p < 0.01 
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Figure 3.12 Kinetics of BAL CXCL1 and IL-5 concentrations in HDM-induced murine asthma 
model 
 
 
 
3.3.3 Kinetics of production of immunoglobulins in the serum 
No distinguishable differences were found in the titers of serum HDM-IgG1, 
HDM-IgG2a and total IgE between HDM-sensitized mice and control mice at both time 
points. 
3.3.4 Kinetics of histological observations in the lung tissue 
The sensitized mice developed goblet cell hyperplasia and mucus hypersecrection 
24 hours after the last instillation of HDM1, which continued at the second time point, 
48 hours after the last instillation (Figure 3.13). 
 
 
 
 
 
BALB/c mice (n = 5 per group) were instilled intranasally with 100 µg HDM1 once a week for 4 
times. 24 hours and 48 hours after the last instillation of HDM1, the mice were sacrificed, 
respectively, and protein levels of CXCL1 and IL-5 in the BAL fluid were determined by ELISA. *p < 
0.05, **p < 0.01 
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Figure 3.13 Kinetics of histological observations in HDM-induced murine asthma model 
 
 
 
 
 
 
3.3.5 Differential cytokine production from in vitro restimulated lymphocytes 
Kinetic assessment of cytokine production of HDM-restimulated lymphocytes 
revealed that between the two time points, lymphocytes from HDM-sensitized mice had 
a stronger immune activity at the first time point. As shown in Figure 3.14, lymphocytes 
from the sensitized mice produced a greater amount of IL-4, IFNγ, IL-10, IL-17A and 
GM-CSF 24 hours after the last instillation of HDM1. Meanwhile, the production of 
IL-5, IL-13 and IL-9 showed a rising tendency at the first time point, as compared to the 
second time point. The above mentioned cytokines were not inducible when the 
lymphocytes from PBS-mice were stimulated with HDM in vitro. 
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BALB/c mice (n = 5 per group) were instilled intranasally with 100 µg HDM1 once a week for 4 
times. 24 hours and 48 hours after the last instillation of HDM1, the mice were sacrificed, 
respectively, and proportion of goblet cells and the volume of mucus content were determined by 
use of microscopic examination and analysis of the software CAST. **p < 0.01 
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Figure 3.14 Differential cytokine productions from in vitro restimulated lymphocytes in HDM-induced murine asthma model 
  BALB/c mice (n = 5 per group) were instilled intranasally with 100 µg HDM 1 once a week for 4 times. 24 hours and 48 hours after the last instillation of HDM1, 
the mice were sacrificed, respectively. Mediastinal lymphocytes were harvested and restimulated with 50 µg/ml HDM1 for 72 hours in vitro. The levels of 
cytokines IL-4, IL-5, IL-13, IFNγ, IL-10, IL-17A, IL-9 and GM-CSF in the cultured supernatant were determined by using CBA multiplex. To serve as a negative 
control, lymphocytes were incubated with medium. *p < 0.05, **p < 0.01 
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To summarize, in the first part of this study, investigating the influence of different 
origins, doses and time points of HDM extracts on the outcome of the asthmatic 
phenotypes demonstrated the following findings: HDM1 from Allergopharma Co. 
elicited a distinct asthma phenotype with a mixed airway inflammation, an increased 
production of serum HDM-IgG1 and a subsequent histological change. This phenotype 
was more pronounced in mice sensitized by 100 µg HDM1 than 50 µg HDM1. The 
most prominent feature of this phenotype was that neutrophils were present in parallel 
with eosinophils and constituted the major component of airway inflammation. 
Neutrophils and eosinophils are activated at different time points by different 
chemotactic factors and their activations might represent different biological events.  
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3.4 S. sciuri abolished asthma phenotype in HDM-induced asthma model 
In this experiment, the Gram-positive bacterium S. sciuri was applied as a 
preventive strategy for HDM-induced asthma phenotype. According to sensitization 
protocol 3 (Figure 2.3), the mice received S. scirui and HDM1 via the airways. 24 hours 
and 48 hours after the last instillation of HDM1, asthma-related parameters were 
compared between HDM-mice with S. sciuri treatment and without S. sciuri treatment. 
The bacterial strain S. sciuri was isolated from the dust of a farm cowshed and 108 CFU 
were used for each treatment. HDM1 was provided by Allergopharma Co. (see Table 
3.4) and 100 µg of the whole extract was given to the mice for each sensitization.  
This was the first time to investigate the influential role of S. sciuri in 
HDM-induced asthma model. It should be mentioned that various biological events at 
the two check points in HDM-mice were demonstrated in Chapter 3.3. In this chapter, 
focus lies on phenotypic changes in HDM-sensitized mice when treated with S. sciuri. 
To exclude potential pathogenicity from S. sciuri, mice only treated with the bacterium 
served as negative control. 
Table 3.4 A brief data sheet of HDM1 
Name Company Batch No. Der p 1 content Der p 2 content Protein content 
HDM1 Allergopharma  W0657678 4.49 µg/100 µg 
HDM 
2.35 µg/100 µg 29 µg/100 µg 
HDM 
3.4.1 S. sciuri attenuated airway inflammation in HDM-induced murine asthma 
model 
As shown in Figure 3.15 (A), sensitization of the mice with HDM1 led to a 
significant rise in airway reactivity, which was not reversed by administration of S. 
sciuri. However, HDM-induced airway inflammation was attenuated by the bacterium S. 
sciuri. As shown in Figure 3.15 (B), at the first time point, 24 hours after the last 
instillation of HDM1, administration of S. sciuri significantly reduced the neutrophil 
cell count in HDM-sensitized mice. At this time point, administration of the bacterium 
did not change the counts of eosinophils, lymphocytes, or macrophages in 
HDM-sensitized mice. At the second time point, 48 hours after the last instillation, the 
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count of neutrophils as well as that of eosinophils in HDM-sensitized mice was 
markedly reduced by the bacteria, while the counts of lymphocytes and macrophages in 
HDM-mice were not changed by the bacteria. 
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Figure 3.15 S. sciuri attenuated airway inflammation in HDM-induced murine asthma model 
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BALB/c mice (n = 5 per group) were instilled intranasally with 100 µg HDM1 once a week for 4 
times. Treatment of S. sciuri was carried out nine days before the first instillation of HDM1, three 
times in one week, until the last instillation. (A) 12 hours after the last instillation, aiway reactivity 
was measured by Head-out body plethysmography. (B) 24 hours and 48 hours after the last 
instillation, the mice were sacrificed, respectively, and cell differentiation of leukocytes in the BAL 
fluid was performed. *p < 0.05, **p < 0.01 
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3.4.2 S. sciuri lowered levels of BAL cytokines and chemokines in HDM-induced 
murine asthma model 
In addition to attenuating airway inflammation, pre-treatment of S. sciuri in 
HDM-mice prevented the secretion of CXCL1 and IL-5 into the BAL fluid at the first 
time point (24 hours after the last instillation). At the second time point, 48 hours after 
the last instillation, the level of CXCL1 in HDM-mice was still lowered by the bacteria, 
while the level of IL-5 in HDM-sensitized mice recovered to a normal level. The 
chemokine CCL11 (eotaxin) was not detectable at both time points.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.16 S. sciuri lowered protein levels of BAL CXCL1 and IL-5 in HDM-induced murine 
asthma mode 
 
 
 
 
 
 
 
3.4.3 S. sciuri exerted no effect on the production of serum immunoglobulins in 
HDM-induced murine asthma model 
No apparent effects on the titers of HDM-IgG1, HDM-IgG2a and total IgE were 
exerted in HDM-mice when pre-treated with S. sciuri. 
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BALB/c mice (n = 5 per group) were instilled intranasally with 100 µg HDM1 once a week for 4 
times. Treatment of S. sciuri was carried out nine days before the first instillation of HDM1, three 
times in one week, until the last instillation. 24 hours and 48 hours after the last instillation, the mice 
were sacrificed, respectively. Protein levels of CXCL1 and IL-5 in the BAL fluid were determined 
by ELISA. *p < 0.05, **p < 0.01 
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3.4.4 S. sciuri alleviated goblet cell hyperplasia and mucus hypersecretion in 
HDM-induced murine asthma model 
As depicted in Figure 3.17, pre-treatment of S. sciuri in HDM-sensitized mice 
reduced the percentage of goblet cells and the volume of mucus content. This 
histological change was observed at both time points.  
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Figure 3.17 S. sciuri abolished goblet cell hyperplasia and mucus hypersecretion in HDM-induced 
murine asthma model 
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(B) 
BALB/c mice (n = 5 per group) were instilled intranasally with 100 µg HDM1 once a week for 4 
times. Treatment of S. sciuri was carried out nine days before the first instillation of HDM1, three 
times in one week, until the last instillation. 24 hours and 48 hours after the last instillation, the mice 
were sacrificed, respectively, and the lungs were subjected to histological examinations. (A) 
Representative photomicrographs of PAS-stained lung sections. (B) Proportion of goblet cells and the 
volume of mucus content were determined by using the software CAST. **p < 0.01 
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3.4.5 S. sciuri inhibited cytokine productions from in vitro restimulated 
lymphocytes in HDM-induced murine asthma model 
Pre-treatment of S. sciuri had an inhibitory impact on cytokine production from 
HDM-restimulated lymphocytes at the first time point. As shown in Figure 3.18, the 
levels of IL-4, IL-5, IL-13, IFNγ, IL-10 and IL-17A were significantly lower in 
HDM-mice with S. sciuri treatment than without treatment, while the levels of IL-9 and 
GM-CSF were not significantly affected by S. sciuri treatment. At the second time point, 
the levels of the above detected cytokines in HDM-mice with or without bacterium 
treatment were comparable to those of PBS-mice.  
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Figure 3.18 (to be continued) S. sciuri inhibited cytokine production from in vitro restimulated lymphocytes in HDM-induced murine asthma model 
 
 
 
 
 
 
BALB/c mice (n = 5 per group) were instilled intranasally with 100 µg HDM1 once a week for 4 times. Treatment of S. sciuri was carried out nine days before the 
first instillation of HDM1, three times in one week, until the last instillation. 24 hours and 48 hours after the last instillation, the mice were sacrificed, respectively. 
Mediastinal lymphocytes were harvested and restimulated with 50 µg/ml HDM1 for 72 hours in vitro. The levels of cytokines IL-4, IL-5, IL-13, IFNγ, IL-10, 
IL-17A, IL-9 and GM-CSF in the cultured supernatant were determined by using CBA multiplex. To serve as negative control, lymphocytes were incubated with 
medium. *p < 0.05, **p < 0.01 
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Figure 3.18 (continued) S. sciuri inhibited cytokine production from in vitro restimulated lymphocytes in HDM-induced murine asthma model 
 
 
 
 
BALB/c mice (n = 5 per group) were instilled intranasally with 100 µg HDM1 once a week for 4 times. Treatment of S. sciuri was carried out nine days before the 
first instillation of HDM1, three times in one week, until the last instillation. 24 hours and 48 hours after the last instillation, the mice were sacrificed, respectively. 
Mediastinal lymphocytes were harvested and restimulated with 50 µg/ml HDM1 for 72 hours in vitro. The levels of cytokines IL-4, IL-5, IL-13, IFNγ, IL-10, 
IL-17A, IL-9 and GM-CSF in the cultured supernatant were determined by using CBA multiplex. To serve as negative control, lymphocytes were incubated with 
medium. *p < 0.05, **p < 0.01 
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3.4.6 S. sciuri repressed the mRNA expressions of asthma-related genes in 
HDM-induced murine asthma model 
As shown in Figure 3.19, pre-treatment of S. sciuri abrogated the upregulation of 
mRNA expression of immune response genes CXCL1, CCL11 (eotaxin), CCL17, IL-4, 
IL-5 and IL-13 in HDM-sensitized mice.  
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Figure 3.19 S. sciuri repressed the mRNA expressions of asthma-related genes in HDM-induced 
murine asthma model 
 
 
 
 
 
 
BALB/c mice (n = 5 per group) were instilled intranasally with 100 µg HDM1 once a week for 4 
times. Treatment of S. sciuri was carried out nine days before the first instillation of HDM1, three 
times in one week, until the last instillation. 24 hours and 48 hours after the last instillation, the mice 
were sacrificed, respectively. The lungs were homogenized and mRNA expression of the 
asthma-related genes CXCL1, CCL11 (eotaxin), CCL17, IL-4, IL-5 and IL-13 were quantified by 
QPCR. *p < 0.05, **p < 0.01 
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3.5 The inhibitory role of S. sciuri in high dose HDM-induced murine asthma 
model 
It was reported that higher dose of HDM extract induced a stronger asthma 
phenotype (Ward et al., 2011). But could S. sciuri still provide protection in such a 
model? In this experiment, 345 µg of the whole extract HDM1, which equals to 100 µg 
of the total protein, was used instead of 100 µg HDM1 to sensitize the mice. 
Administrations of S. sciuri and HDM1 were carried out according to sensitization 
protocol 3 (Figure 2.3). 24 hours and 48 hours after the last instillation of HDM1, the 
mice were sacrificed and asthma-related parameters were analyzed dynamically. The 
bacterial strain S. sciuri was isolated from the dust of a farm cowshed and HDM1 was 
provided by Allergopharma Co. (see Table 3.5). To exclude pathogenicity from S. 
sciuri, mice only treated with the bacterium served as negative control. 
Table 3.5 A brief data sheet of HDM1 
Name Company Batch No. Der p 1 content Der p 2 content Protein content 
HDM1 Allergopharma  W0657678 4.49 µg/100 µg 
HDM 
2.35 µg/100 µg 29 µg/100 µg 
HDM 
3.5.1 S. sciuri inhibited neutrophil but not eosinophil airway inflammation in 
high dose HDM-induced murine asthma model 
It was observed that HDM1 at a dose of 345 µg still elicited a mixed inflammation 
of neutrophils and eosinophils. This airway inflammation was only partially inhibited 
by administration of S. sciuri. As shown in Figure 3.20, in mice sensitized by HDM1, a 
substantial number of neutrophils and eosinophils fluxed into the airway 24 hours after 
the last instillation of HDM1, while administration of S. sciuri prevented the influx of 
neutrophils, but not eosinophils. 48 hours after the last instillation of HDM1, 
neutrophils were still inhibited by the bacterial treatment.  
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Figure 3.20 S. sciuri inhibited neutrophil but not eosinophil airway inflammation in high dose 
HDM-induced murine asthma model 
 
 
 
 
 
 
3.5.2 S. sciuri prevented the secretion of BAL CXCL1, but not IL-5 in high dose 
HDM-induced murine asthma model 
Sensitizing of HDM1 at a dose of 345 µg elicited a hypersecrection of BAL 
CXCL1 and IL-5 at the first time point. At the second time point, the level of CXCL1 
remained higher in HDM-sensitized mice than in PBS-mice, while IL-5 returned to a 
normal level. This hypersecretion of CXCL1 in HDM-sensitized mice was prevented 
BALB/c mice (n = 4 per group) were instilled intranasally with 345 µg HDM1 once a week for 4 times. 
Treatment of S. sciuri was carried out nine days before the first instillation of HDM1, three times in one 
week, until the last instillation. 24 hours and 48 hours after the last instillation, the mice were sacrificed, 
respectively, and cell differentiation of leukocytes in the BAL fluid was performed. *p < 0.05, **p < 0.01 
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by administration of S. sciuri, while IL-5 was not affected by the bacteria. The 
chemokine CCL11 (eotaxin) was undetectable in all groups (see Figure 3.21). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.21 S. sciuri prevented the secretion of BAL CXCL1, but not IL-5 in high dose 
HDM-induced murine asthma model 
 
 
 
 
 
 
3.5.3 S. sciuri had no effect on the production of serum HDM-IgG1 in high dose 
HDM-induced murine asthma model 
As shown in Figure 3.22, sensitization of the mice with 345 µg HDM1 led to a 
significant increase in serum HDM-IgG1 24 hours after the last instillation. At this 
time point, no HDM-IgG2a was detectable in HDM-sensitized mice and the level of 
total IgE remained comparable to that of PBS-mice. 48 hours after the last instillation, 
no significant difference in the titers of the the serum immunoglobulins (HDM-IgG1, 
HDM-IgG2a and total IgE) was found between the sensitized mice and non-sensitized 
mice. Pre-treatment of S. sciuri had no obvious effect on the production of HDM-IgG1 
or HDM-IgG2a in HDM-sensitized mice. In contrast, the production of total IgE in 
HDM-mice was moderately lowered when treated with S. sciuri.  
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BALB/c mice (n = 4 per group) were instilled intranasally with 345 µg HDM1 once a week for 4 
times. Treatment of S. sciuri was carried out nine days before the first instillation of HDM1, three 
times in one week, until the last instillation. 24 hours and 48 hours after the last instillation, the mice 
were sacrificed, respectively. Protein levels of CXCL1 and IL-5 in the BAL fluid were determined by 
ELISA. *p < 0.05, **p < 0.01 
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Figure 3.22 S. sciuri had no effect on serum HDM-IgG1 in high dose HDM-induced murine 
asthma model 
 
 
 
 
 
 
 
3.5.4 S. sciuri alleviated goblet cell hyperplasia and mucus hypersecretion in 
high dose HDM-induced murine asthma model 
At both time points, goblet cell hyperplasia and mucus hypersecretion were 
observed in mice sensitized by 345 µg HDM1, which were reversed by administration 
of the bacterium S. sciuri (see Figure 3.23).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HDM-IgG1
PB
S/
PB
S
PB
S/
HD
M
1
Sc
i/P
BS
Sc
i/H
DM
1
PB
S/
PB
S
PB
S/
HD
M
1
Sc
i/P
BS
Sc
i/H
DM
1
0.0
0.2
0.4
0.6
0.8
1.0
* *
*
24 h                       48 h
O
D
4
5
0
 (
A
b
s
-B
la
n
k
)
 
HDM-IgG2a
PB
S/
PB
S
PB
S/
HD
M
1
Sc
i/P
BS
Sc
i/H
DM
1
PB
S/
PB
S
PB
S/
HD
M
1
Sc
i/P
BS
Sc
i/H
DM
1
0.0
0.1
0.2
0.3
0.4
24 h                       48 h
O
D
4
5
0
 (
A
b
s
-B
la
n
k
)
 
Total IgE
PB
S/
PB
S
PB
S/
HD
M
1
Sc
i/P
BS
Sc
i/H
DM
1
PB
S/
PB
S
PB
S/
HD
M
1
Sc
i/P
BS
Sc
i/H
DM
1
0
100
200
300
400
500
p=0.055
24 h                       48 h
O
D
4
5
0
 (
A
b
s
-B
la
n
k
)
  
BALB/c mice (n = 4 per group) were instilled intranasally with 345 µg HDM1 once a week for 4 times. 
Treatment of S. sciuri was carried out nine days before the first instillation of HDM1, three times in one 
week, until the last instillation. 24 hours and 48 hours after the last instillation, the mice were sacrificed, 
respectively. The titers of serum HDM-IgG1, HDM-IgG2a and total IgE were determined by ELISA. *p 
< 0.05, **p < 0.01 
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Figure 3.23 S. sciuri alleviated goblet cell hyperplasia and mucus hypersecretion in high dose 
HDM-induced murine asthma model 
  
 
 
 
 
 
 
 
3.5.5 S. sciuri diminished cytokine productions from in vitro restimulated 
lymphocytes in high dose HDM-induced murine asthma model 
In mice sensitized by 345 µg HDM1, the restimulated lymphocytes showed 
increased activity with regards to cytokine production at the first time point. As shown 
in Figure 3.24, HDM-restimulated lymphocytes from the sensitized mice produced a 
higher level of IL-5, IL-13, IFNγ, IL-10 and IL-9 at the first time point, compared with 
the second time point. The levels of IL-4, TNFα and G-CSF were comparable between 
the two time points. The above mentioned cytokines were not inducible when the 
lymphocytes from PBS-mice were stimulated with HDM1 in vitro. 
Admininstration of S. sciuri diminished the cytokine producing activity of 
lymphocytes in HDM-sensitized mice, in which the levels of IL-4, IL-5, IL-13, IFNγ, 
IL-10 and IL-9 were markedy reduced, while the level G-CSF remained unaffected by 
the bacterial treatment.  
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BALB/c mice (n = 4 per group) were instilled intranasally with 345 µg HDM1 once a week for 4 
times. Treatment of S. sciuri was carried out nine days before the first instillation of HDM1, three 
times in one week, until the last instillation. 24 hours and 48 hours after the last instillation, the mice 
were sacrificed, respectively, and proportion of goblet cells and the volume of mucus content were 
determined by use of microscopic examination and analysis of the software CAST. *p < 0.05,      
**
p < 0.01 
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Figure 3.24 (to be continued) S. sciuri diminished cytokine production from in vitro restimulated lymphocytes in high dose HDM-induced murine asthma 
model 
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BALB/c mice (n = 4 per group) were instilled intranasally with 345 µg HDM1 once a week for 4 times. Treatment of S. sciuri was carried out nine days before the 
first instillation of HDM1, three times in one week, until the last instillation. 24 hours and 48 hours after the last instillation, the mice were sacrificed, respectively. 
Mediastinal lymphocytes were harvested and restimulated with 172.5 µg/ml HDM1 for 72 hours in vitro. The levels of cytokines IL-4, IL-5, IL-13, IFNγ, IL-10, 
IL-9 and G-CSF in the cultured supernatant were determined by using CBA multiplex. To serve as a negative control, lymphocytes were incubated with medium.  
*
p < 0.05, **p < 0.01 
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 Figure 3.24 (continued) S. sciuri diminished cytokine production from in vitro restimulated lymphocytes in high dose HDM-induced murine asthma model 
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BALB/c mice (n = 4 per group) were instilled intranasally with 345 µg HDM1 once a week for 4 times. Treatment of S. sciuri was carried out nine days before the 
first instillation of HDM1, three times in one week, until the last instillation. 24 hours and 48 hours after the last instillation, the mice were sacrificed, respectively. 
Mediastinal lymphocytes were harvested and restimulated with 172.5 µg/ml HDM1 for 72 hours in vitro. The levels of cytokines IL-4, IL-5, IL-13, IFNγ, IL-10, 
IL-9 and G-CSF in the cultured supernatant were determined by using CBA multiplex. To serve as a negative control, lymphocytes were incubated with medium.  
*p < 0.05, **p < 0.01 
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To summarize, in the second part of this study, administration of the bacterium S. 
sciuri had an extensive impact on the reduction of HDM-induced murine asthma 
phenotype, which was demonstrated as follows: intranasal administration of S. sciuri 
before HDM sensitization alleviated both neutrophil and eosinophil airway 
inflammation, inhibited the secretion of CXCL1 and IL-5 into the BAL fluid and the 
production of cytokines IL-4, IL-5, IL-10, IL-13, IFNγ, IL-17A from the restimulated 
lymphocytes, and altered the histological manifestations by inhibiting goblet cell 
hyperplasia and mucus hyperproduction, whereas administration of S. sciuri in 
HDM-sensitized mice had no apparent effect on airway reactivity and the production of 
serum immunoglobulins. In mice sensitized by a higher dose of HDM1 (345µg), 
administration of S. sciuri only inhibited neutrophil airway inflammation, but not 
eosinophils.  
Administration of S. sciuri alone without HDM sensitization did not lead to 
asthmatic manifestations in the mouse model, which was evidenced by the following: in 
mice which only received the bacteria, the counts of total leukocytes, neutrophils, 
eosinophils and lymphocytes remained comparable to that of PBS-mice, whereas the 
count of macrophages was significantly higher than that of PBS-mice at the second time 
point; the level of IL-5 and CCL11 were not detectable, whereas CXCL1 was found to 
be significantly higher at the second time point as compared to PBS-mice; the titers of 
serum immunoglobulins (HDM-IgG1, HDM-IgG2a, and total IgE) were comparable to 
that of PBS mice; no obvious production of the cytokines (IL-4, IL-5, IL-10, IL-13, 
IFNγ, IL-17A, IL-9, GM-CSF) were induced from the lymphocytes when stimulated 
with HDM1 in vitro; the percentage of goblet cells and the volume of mucus content 
remained comparable to those of PBS-mice. However, in mice which only received the 
bacteria, airway reactivity was significantly higher than that of PBS-mice. 
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4 Discussion 
Allergic asthma is an inflammatory airway disease which develops based on 
gene-environment interactions. It is characterized by intense infiltration of airway 
inflammatory cells, increased airway responsiveness and reversible airway obstruction. 
This disease was initially thought to be Th2-dominated, in which eosinophils and 
lymphocytes were the predominating cells infiltrated in the airways and a limited set of 
cytokines including IL-4 and IL-5 were detected (Jeffery, 1992; Groot et al., 2002). 
Therefore, research into the underlying mechanisms of asthma pathogenesis was mainly 
focused on Th2 immune responses and the most frequently used model allergen OVA 
has gained great achievements in mimicking this subtype of asthma, namely eosinophil 
asthma phenotype or Th2-high asthma phenotype. Therapeutically, targeting eosinophil 
biology or Th2 cytokine such as IL-5 has been proved to be effective in asthma 
treatment (Wegmann, 2011; Sel et al., 2008; Wegmann et al., 2007; Molfino et al., 
2011). 
However, novel subtypes of asthma such as non-eosinophilic asthma phenotype has 
been identified and strategies of targeting eosinophils or Th2 cytokines may not be 
sufficient for the various phenotypes. The sensitizing allergen exploited in murine 
asthma models has shifted from the surrogate OVA to HDM extracts for the benefit of 
clinical relevance (Gregory et al., 2011). Recent studies demonstrated that HDM 
allergens not only induced an adaptive Th2 immune response, but also orchestrated 
innate immune pathways such as TLR4 or Toll/IL-1 signalling (Jacquet, 2011; Hammad 
et al., 2009; Phipps et al., 2009), in which airway neutrophilia is a recognised feature.  
The Hygiene hypothesis has gained much attention and been frequently confirmed 
in the studies of allergic diseases. In OVA asthma models, some microbes including 
Bordetella pertussis, Chlamydia, A. lwoffii F78 and Lactococcus lactis have been shown 
to counteract eosinophilic airway inflammation and provide protection against asthma. 
In the study of Ege and coworkers, the Gram-positive bacterium S. sciuri has been 
indicated as a protective factor in childhood asthma (Ege et al., 2011); yet this 
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asthma-protective effect has not been proven in a murine model so far. Therefore, the 
present study was designed to evaluate the potential effect of S. sciuri on HDM-induced 
murine asthma phenotype with a mixed neutrophil and eosinophil airway inflammation. 
4.1 Allergic airway inflammation was elicited by intranasal sensitization of HDM 
extract 
Current knowledge emphasizes that asthma development is a complex process 
resulting from interactions between genetic predisposition and environmental exposure 
(Renz et al., 2011; Mukherjee et al., 2011). Just like other allergic diseases, asthma is 
hereditary (Holloway et al., 2010). Children from asthmatic families are thought to be 
predisposed to asthma. Many powerful genetic tools were used to investigate the 
heritable component of asthma and recent genome-wide association studies (GWASs) 
identified more than 100 genes in 22 chromosomes as susceptibility factors for allergic 
asthma (Malerba et al., 2005; Vercelli, 2008). The list of asthma candidate genes is 
likely to expand in the coming years. However, most of the genes have only mild effects. 
Instead, environmental milieu was supposed to have a determinant function. It is 
generally agreed that multiple genes influence disease phenotypes through their 
interactions with the environment (Kleeberger et al., 2005) and even without any 
apparent genetic predisposition some individuals can develop asthma after exposure to 
environmental factors. Understanding the precise role of environmental exposure in the 
development of asthma is critical for understanding this disease (Schwartz, 2009). In 
contrast to genetic studies, research into the environmental field is still at an early stage. 
Despite the constantly increasing evidence for gene-environment effects in asthma 
pathogenesis, it is still obscure which environmental factors might be linked to a 
specific gene set (Kleeberger et al., 2005). Investigation of environmental effects in 
human subjects is still constrained due to variations across populations and the presence 
of ethical and technical issues. Compared with humans, mouse models are easily 
reproducible with a fixed genetic background and genetically more tractable, in which a 
strict genetic or environmental control could be achieved. Meanwhile, mouse models 
provide a fast and economic way to assess gene-environment relationship. 
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With the recognition of environmental effects on disease progression, it is now 
realized that some environmental factors might trigger disease onset, while other factors 
may confer disease protection. The double effects were observed in our models as well, 
which would be discussed separately. This part was mainly focused on the sensitizing 
effect of HDM extracts. In our models, HDM extract as an environmental allergen 
produced a profound effect on the development of an asthma phenotype. The three 
different origins of HDM extracts, which varied in their contents such as Der p 1 
concentration, displayed unequal performance in eliciting airway inflammation. Among 
them, HDM1 (from Allergopharma Co.) induced the most robust influx of both 
neutrophils and eosinophils into the airways, HDM2 (from Greer Labs) exerted stronger 
effect on the induction of neutrophil airway inflammation, while HDM3 (from Greer 
Labs) only elicited a very weak inflammatory response. The divergent inflammatory 
responses induced by the three different extracts could be attributed to their diversity in 
relative composition and extract methods. In line with this, Post (Post et al., 2011) 
demonstrated that the composition of house dust mite extract has a crucial effect on 
epithelial remodeling and airway inflammation. Besides composition, different doses of 
HDM extracts had different inflammation-promoting abilities. The sensitizing dose 
could influence the aggregation of inflammatory cells and the production of BAL 
cytokines and chemokines and eventually affect asthma pathogenesis (Kurup et al., 
2001). In regard to this, Delayre-Orthez proved that effects of endotoxins on allergen 
sensitization and challenge were dose-dependent (Delayre-Orthez et al., 2004). And in 
the study of Ward and coworkers (Ward et al., 2011), HDM-challenged mice displayed a 
dose-dependent increase in neutrophil, eosinophil and lymphocyte counts. Consistent 
with the data, our results showed that in mice sensitized by 10 µg HDM, no obvious 
asthmatic response was observed, while 100 µg HDM extract elicited a more distinct 
asthma phenotype than 50 µg HDM extract. It was proposed that even a higher dose of 
HDM extract (345 µg) would have a stronger effect than 100 µg, although no direct 
comparison was performed between the two doses. Just like with the other allergens, 
severity of the HDM effect could also rely on the sensitizing time. Due to different 
protocols employed in different studies, the optimum time for HDM sensitization is still 
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in debate. HDM extract was initially adopted by Cates et al. (Cates et al., 2004) to 
model acute allergic airway inflammation via the respiratory mucosa. They 
demonstrated that intranasal administration of HDM extract for 10 days without 
adjuvant provoked a Th2-type sensitization. Following this, numerous data of HDM 
models have been reported, but with wide variations. Our data revealed that intranasal 
instillation of HDM for 4 times in three weeks elicited a distinct asthma phenotype in 
the mouse model. 
The pronounced effect of HDM extract on the induction of an asthma phenotype 
could be demonstrated by several biological observations in the present study. First of 
all, HDM sensitization resulted in the most unique feature of airway inflammation, 
which was dominated by neutrophils and eosinophils. As an early event, a large amount 
of neutrophils migrated into the airways 24 hours after the last instillation of HDM 
extract. This migration was possibly associated with the activations of cytokines and 
chemokines including CXCL1, IL-17 and IFNγ. CXCL1 has been identified as a potent 
neutrophil chemotactic factor both in vivo and in vitro (Bozic et al., 1995). Post and 
coworkers (Post et al., 2011) demonstrated that in HDM-treated mice, increased levels 
of CXCL1 were accompanied by increased numbers of neutrophils. This study revealed 
that in HDM-sensitized mice, both mRNA and protein expressions of CXCL1 were 
upregulated. Similar to CXCL1, IL-17 was induced by HDM sensitization at both 
mRNA and protein levels. IL-17 is a proinflammatory factor, which is known to induce 
productions of other cytokines and chemokines, especially CXCL1 (the human 
homologue of IL-8) (Breslow et al., 2011). IL-17 has been associated with severe 
asthma, in which much greater airway neutrophilia was recognized (Lajoie et al., 2010; 
Shannon et al., 2008). It was reported that increased levels of IL-17 could facilitate 
neutrophil infiltration (Witowski et al., 2004), and the production of IL-17 could be 
induced by rIL23 or HDM extract (Kohyama et al., 2007; Wu et al., 2007; Post et al., 
2011). A third inflammatory factor increased by HDM sensitization is IFNγ. The 
interactions of IFNγ and neutrophils have been underestimated (Ellis et al., 2004). In the 
present study, the increased production of IFNγ from restimulated lymphocytes was 
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possible related to neutrophil airway inflammation. In support of this, Yoshimura 
(Yoshimura et al., 2007) demonstrated that IFN-γ effectively prolonged the survival of 
activated neutrophils. Additionally, HDM sensitization increased the mRNA and protein 
expressions of IL-10, an anti-inflammatory cytokine studied by numerous investigations. 
Due to controversial results obtained from different studies (Finkelman et al., 2010; 
Bettiol et al., 2002; Fu et al., 2006; Oh et al., 2002; Presser et al., 2008), the precise role 
of IL-10 in asthma pathogenesis is still not determined.   
In comparison with neutrophils, recruitment of airway eosinophils occurred at a 
later time point after HDM sensitization. The activation of eosinophils was possibly 
related to upregulation of Th2 cytokines (IL-4, IL-5 and IL-13) and the inflammatory 
factor GM-CSF. Firstly, the elevation of IL-5 in mRNA and protein levels might 
contribute directly to the airway eosinophilia (Finkelman et al., 2010). Among the three 
classic Th2 cytokines (IL-4, IL-5 and IL-13), IL-5 is the best characterized for 
influencing eosinophil biology through the binding of IL-5R on eosinophil surface, and 
in humans IL-5 acts mainly on eosinophils and their precursors. It was reported that in 
murine asthma models overexpression of IL-5 in the lung led to spontaneous 
development of eosinophilic airway inflammation and IL-5 deficiency abolished this 
eosinophilia (Lee et al., 1997; Foster et al., 2012). It was also reported that anti-IL-5 
mAb treatment in clinical asthma patients caused a considerable decrease in blood 
eosinophilia and a partial decrease in lung eosinophilia (Leckie et al., 2000; Flood-Page 
et al., 2003). In the present study, IL-5 protein levels were found to be increased in the 
BAL. In the in vitro restimulated lymphocytes the increase of IL-5 was accompanied by 
the increase of IL-4 and IL-13, two other cytokines which might exert indirect 
eosinophil-promoting effect. One feasible explanation for IL-4 and IL-13 inducing 
eosinophil activation is that both IL-4 and IL-13 signal through the type II IL-4R to 
induce production of chemokines, including eotaxin-1 (CCL11) and eotaxin-2 (CCL24), 
which attract eosinophils to the lungs (Finkelman et al., 2010; Munitz et al., 2008). 
Compared with IL-5, IL-4 and IL-13 worked more broadly in multiple pathways in the 
pathogenesis of asthma, which will be discussed later. In addition to the three Th2 
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cytokines, HDM sensitization increased the production of GM-CSF, a cytokine which 
was also implicated in eosinophil trafficking (Pope et al., 2001). As GM-CSF shares a 
common β chain receptor, it was deduced that GM-CSF and IL-5 may share some 
signaling pathway which regulated esinophil differentiation, proliferation and survival 
(Molfino et al., 2011).  
Although neutrophils and eosinophils constituted the major part of airway 
inflammation elicited by HDM extract, epithelial cells may play a critical part in the 
initiation of this inflammation. It is generally thought that the respiratory epithelium 
senses the signals produced by constant contacts of allergens and develops active 
responses (Holgate, 2011). The airway epithelium is a well-established sources of 
cytokines and chemokines (Müller et al., 2005). In vitro studies have demonstrated that 
stimulation of respiratory epithelium by HDM extract led to secretion of different 
chemokines such as CCL20 (Nathan et al., 2009). Our results indicated HDM 
sensitization activated epithelial cells possibly through the upregulation of chemokine 
genes CXCL1, CCL11 (eotaxin) and CCL17. The three genes share the same cellular 
source, epithelial cells, but exerted different chemotactic capabilities. Among them, 
CXCL1 was expected to be responsible for neutrophil migration, CCL11 might be 
associated with eosinophil recruitment (Finkelman et al., 2010), and CCL17 was 
probably related to the chemotaxis of Th2 cells (Yao et al., 2011). Based on the above 
data, it was proposed that both innate and adaptive immune mechanisms were involved 
in the development of allergic airway inflammation in HDM-sensitized together with a 
strong involvement of epithelial cell activation.  
In addition to airway inflammation, further features of an asthmatic response were 
also induced by HDM exposure including overproduction of HDM-specific IgG1 and 
goblet cell hyperplasia, which have been frequently indicated in the studies of allergic 
airway diseases (Kaneko et al., 1995; Ishikawa et al., 2011; Wegmann et al., 2005; 
Vermeer et al., 2003). The structural changes of the airways such as goblet cell 
hyperplasia and mucus hypersecrection were probably correlated with the elevation of 
IL-13 (Tanabe et al., 2011)(Zhu et al., 1999). Also, it should be noted that the airway 
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reactivity in HDM-sensitized mice did not correspond to the development of airway 
inflammation. Although the dissociation of airway hyperresponsiveness from airway 
inflammation was not uncommon, a definite explanation is still lacking. It was argued 
that AHR was influenced by the genetic background of the mouse, the method used, the 
time point of analysis, etc. In our case, airway reactivity was measured by Head-out 
body plethysmography, a non-invasive method, which may not directly correlate with 
changes in airway resistance (Bates et al., 2004). Therefore, it would be recommended 
to confirm these results by an invasive measurement for airway reactivity. 
Collectively, our results demonstrated that HDM extract was a critical determinant 
for the development of a distinct murine asthma phenotype, which was characterized by 
a unique airway inflammation of neutrophils and eosinophils, an augmented IgG1 
response and subsequent histological changes. The pathogenesis of this phenotype was a 
complex process, with multiple components involved in. The unique gene expression 
pattern further suggested that the initiation of the unique airway inflammation was 
possibly due to a specific activation of airway epithelial cells. 
4.2 Administration of S. sciuri as a possible preventive strategy for 
HDM-induced asthma phenotype 
Environmental exposure has been proven to have a significant impact on the 
progression of allergic disease including asthma (Wahn, 2011). On one hand, exposure 
to environmental factors such as house dust mites, cockroaches and cat dander was 
considered as a dominant risk factor for the development or exacerbation of asthma in 
sensitized individuals (Sporik et al., 1999; Squillace et al., 1997; Litonjua et al., 2001; 
Polk et al., 2004). On the other hand, exposure to microbial compounds was found to 
influence the development of adaptive immunity and the resulting allergy possibly 
through the modulation of innate immune responses (Gregory et al., 2011; 
Braun-Fahrländer et al, 2002). The hygiene hypothesis predicts that infections may 
protect against asthma, which has been addressed by numerous studies. In Celedón’s 
survey, it was concluded that early endotoxin exposure may be a protective factor 
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against atopy (Celedón et al., 2007). Epidemiological studies performed in Europe have 
frequently demonstrated that children raised on farms had a lower prevalence of asthma 
than those who lived in cities (Von Ehrenstein et al, 2000; Barnes et al., 2001; Riedler et 
al., 2000; Riedler et al., 2001; Ege et al., 2011). The most striking finding was that 
specific environmental exposure correlated with increased expression of specific genes 
(Ege et al., 2007; Vercelli, 2008). For example, haying was correlated with increased 
expression of TLR7 and TLR10, whereas feeding silage was related to higher 
expression of TLR6 and TLR8. Actually, not all farming environments protect against 
the development of asthma in children (Ege et al., 2007). Mouse models have been used 
to provide a proof-of-concept for the protective effects of farm-derived microbes. 
Acinetobacter lwoffii and Lactococcus lactis were the earliest studied cowshed bacteria, 
which have shown to exert asthma protective effects in mouse models (Debarry et al., 
2007; Conrad et al., 2009; Brand et al., 2011). Meanwhile, other microbes including 
Bacillus licheniformis (Vogel et al., 2008), Bifidobacterium longum AH1206 (Lyons et 
al., 2010), Helicobacter pylori (Arnold et al., 2011), Escherichia coli (Nembrini et al., 
2011), and Broncho-Vaxom (Navarro et al., 2011) have also been shown to modulate 
allergic airway reactions or provide asthma protection.  
Our mouse model provided the first evidence that the potential asthma-preventive 
effect of S. sciuri was tested in a mouse model with a mixed eosinophil and neutrophil 
asthma phenotype, since this bacterium has only been indicated of a protective role in 
childhood asthma (Ege et al., 2011). In our model, intranasal administration of S. sciuri 
before HDM sensitization alleviated the mixed airway inflammation of neutrophils and 
eosinophils, in which the decrease of eosinophils was not accompanied by a tendency 
toward higher neutrophil counts, or vice verse. Additionally, administration of S. sciuri 
in HDM-sensitized mice abrogated the secretion of CXCL1 and IL-5 into the BAL and 
the production of cytokines IL-4, IL-5, IL-10, IL-13, IFNγ, IL-17A from the 
restimulated lymphocytes was also reduced. Histologically, pre-treatment of S. sciuri 
altered the asthmatic manifestations by inhibiting goblet cell hyperplasia and mucus 
hyperproduction. However, administration of S. sciuri in HDM-sensitized mice had no 
Discussion 
Page 77 
apparent effect on airway reactivity and the production of serum immunoglobulins. 
There is accumulating data that microbes could confer allergy protection, yet the 
underlying mechanisms are still conflicting. Previous studies were conducted mostly in 
OVA asthma models, in which eosinophils were the predominant inflammatory cells and 
administration of microbes led to the inhibition of eosinophilc airway inflammation. In 
Debarry’s study (Debarry et al., 2007), it was proposed that the bacteria conducted 
protective effect against allergy possibly through promoting Th1 and inhibiting Th2 
activity. Lyons and colleagues (Lyons et al., 2010) attributed the protective role of 
bacteria to the airway recruitment of regulatory T cells. Brand (Brand et al., 2011) 
recognized that microbes provide asthma protection through epigenetic regulation in a 
prenatal window of opportunity. In the present study, both eosinophils and neutrophils 
constituted the major part of airway inflammation induced by HDM extract. 
Administration of S. sciuri in HDM-mice abrogated the increased mRNA expressions of 
a variety of genes CXCL1, CCL11 (eotaxin), CCL17, IL-4, IL-5 and IL-13, which was 
corresponded by the decreased protein levels of CXCL1, IL-4, IL-5 and IL-13. 
Moreover, protein levels of the cytokines IFNγ and IL-10 were also lowered by the 
bacterium. The distinct gene expression pattern, together with the reduced protein 
productions observed in S. sciuri-treated HDM-mice suggested the protective effect of S. 
sciuri might not be mediated through inducing Th1 or regulatory T cells. An alternative 
proposal was that this bacterium might provide asthma protection through the 
modulation of immune responses, since epithelilal cells are constanly receiving the 
bacterial contact and might act as a master regulator of both innate and adaptive 
immune responses (Bulek et al., 2010).   
Interestingly, this protective role of S. sciuri became weaker when the mice were 
sensitized by 345 µg HDM1. In mice sensitized by this dose of HDM1, administration 
of S. sciuri only inhibited neutrophil airway inflammation, but not eosinophils, 
indicating that neutrophils were more sensitive to the protective effects of S. sciuri than 
eosinophils. Administration of S. sciuri still alleviated goblet cell hyperplasia and mucus 
hypersecretion in mice sensitized by a higher dose of HDM1.   
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Taken together, data obtained from the present study provided the first evidence 
that the bacterium S. sciuri had an extensive effect on the prevention of a mixed murine 
asthma phenotype. Administration of S. sciuri in HDM-sensitized mice led to the 
inhibition of the unique airway inflammation, goblet cell hyperplasia and mucus 
hypersecretion, accompanied by a down regulation of various chemokines and 
cytokines including CXCL1, IL-5, IL-4, IL-10, IL-13, IFNγ and IL-17A.  
These data further supported the concept of hygiene hypothesis in a HDM murine 
asthma model. The possible mechanism by which S. sciuri conducted its protective 
effect might be through the regulation of mRNA expression of immune response genes 
including CXCL1, CCL11 (eotaxin), CCL17, IL-4, IL-5 and IL-13, which was distinct 
from the previous studies. Due to the few number of genes examined, understanding of 
this mechanism is still limited. It’s tempting to fully disclose the relationship between S. 
sciuri and asthma and translate the findings into patient benefit.  
Therefore, it was concluded that intranasal administrations of S. sciuri might serve 
as a promising strategy for asthma prevention. 
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5 Summary 
5.1 Summary 
Allergic asthma is a chronic inflammatory disease of the airways based on a 
dysregulated immune response to innocuous antigens (allergens) with a predominance 
of Th2-driven activities. According to the hygiene hypothesis, neonatal and early 
childhood exposure to certain microbes and their products may protect them from the 
development of allergic responses due to a shift in the balance of T cell subpopulation 
activities. This concept has been experimentally proven for Gram-negative bacteria in a 
mouse model representing an eosinophil granulocyte-dominated phenotype using 
ovalbumin as model allergen. Recently, epidemiological studies revealed a specific 
association between Staphylococcus sciuri exposure and reduced asthma prevalences.  
The aim in the first part of this work was to establish a murine model of allergic 
airway inflammation with a more pronounced contribution of neutrophil granulocytes, 
using the clinically relevant house dust mite (HDM) allergen. Various asthma-relevant 
parameters were monitored after exposure to house dust mite extracts from different 
sources, at a wide range of doses and at various intervals after allergen challenge. It 
could be revealed that HDM1 from Allergopharma Co. (Hamburg, Germany) elicited 
the strongest asthma phenotype with a mixed eosinophil and neutrophil airway 
inflammation, an increased production of serum HDM-IgG1 and subsequent 
histological changes. This phenotype was also more pronounced in mice sensitized with 
the highest tested HDM extract concentration (100 µg). It also became evident that 
neutrophils and eosinophils got involved at different time points of the inflammatory 
process by the action of different chemotactic factors and their activation thus 
representing different biological events. 
In the second part of this work, the Gram-positive bacterium S. sciuri was tested for 
its potential allergy-protective effect in this model. Exposure to S. sciuri strongly 
inhibited the generation of HDM extract-induced airway inflammation, as evidenced by 
a reduction of both eosinophil and neutrophil numbers compared to HDM 
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extract-induced airway inflammation in non-exposed control-animals. This suppression 
of airway inflammation was accompanied by diminished production of cytokines and 
chemokines and by an alleviation of goblet cell hyperplasia and mucus production. 
These data provide the first experimental evidence that exposure to S. sciuri might 
be protective against the development of allergic airway inflammation and associated 
pulmonary pathology.  
5.2 Zusammenfassung 
Das allergische Asthma ist eine chronisch entzündliche Erkrankung der Atmenwege, 
die auf einer dysregulierten Immunantwort gegenüber harmlosen Antigenen (Allergenen) 
mit einer dominanten Th2-Aktivität beruht. Gemäß der Hygienehypothese sind 
Neugeborene und Kinder, die in den ersten Lebensjahren bestimmten Bakterien und 
ihren Produkten ausgesetzt sind, vor der Entwicklung von allergischen Reaktionen 
geschützt. Dies beruht auf einer Verschiebung in der Balance der Aktivitäten 
verschiedener T-Zell-Subpopulationen. Experimentell konnte dieses Konzept bereits für 
Gram-negative Bakterien in einem Maus-Modell mit Ovalbumin als Allergen, welches 
einen von eosinophilen Granulozyten dominierten Phänotyp aufweist, aufgezeigt 
werden. Kürzlich konnte in epidemiologischen Studien eine spezifische Assoziation 
zwischen einer Staphylococcus sciuri Exposition und einer verminderten Asthma 
Prävalenz aufgezeigt werden. 
Das Ziel des ersten Teils der Arbeit war es, ein Maus-Modell der allergischen 
Atemwegsentzündung mit einer verstärkten Beteiligung von neutrophilen Granulozyten 
zu entwickeln. Hierfür wurde als klinisch relevantes Allergen 
Hausstaubmilben(HDM)-Extrakt verwendet. Es wurde der Einfluss von 
HDM-Extrakten verschiedener Quellen, unterschiedlicher Dosen, verschiedene 
Zeitintervalle nach letzter Allergengabe auf Asthma-relevante Parameter untersucht. 
Hierbei konnte gezeigt werden, dass HDM1 von Allergopharma CO. (Hamburg, 
Germany) den stärksten Asthmaphänotyp mit einer gemischten Eosinophilen und 
Neutrophilen Atemwegsentzündung, einer erhöhten  HDM-IgG1-Produktion und 
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entsprechenden histologischen Veränderungen induzierte. Dieser Phänotyp war zudem 
am stärksten in Mäusen ausgeprägt, die mit der höchsten getesteten HDM-Extrakt Dosis 
(100 µg) exponiert wurden. Es konnte außerdem gezeigt werden, dass Neutrophile und 
Eosinophile aufgrund verschiedener chemotaktischer Faktoren und deren Aktivierung 
zu verschiedenen Zeitpunkten des inflammatorischen Prozesses beteiligt sind und ihre 
Aktivierung somit differentielle biologische Ereignisse darstellt. 
Im zweiten Teil dieser Arbeit wurde das Gram-positive Bakterium S. sciuri 
hinsichtlich potentieller allergieprotektiver Eigenschaften in diesem Modell getestet. 
Exposition des Bakteriums S. sciuri führte zu einer sehr ausgeprägten Verminderung der 
HDM-induzierten Atemwegsentzündung. Dies spiegelte sich in einer Verminderung 
sowohl der Zahl eosinophiler als auch neutrophiler Granulozyten, im Vergleich zu den 
nicht S. sciuri-exponierten Kontrolltieren wider. Parallel zur reduzierten 
Atemwegsentzündung wurde eine verminderte Produktion von Zytokinen und 
Chemokinen und eine Abschwächung der Goblet-Zell-Hyperplasie und 
Mukus-Produktion beobachtet. 
Diese Daten geben erste experimentelle Hinweise darauf, dass die Exposition mit S. 
sciuri eine protektive Wirkung auf die Entwicklung einer allergischen 
Atemwegsentzündung und damit assoziierter pulmonärer Pathology haben kann. 
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A. lwoffii F78 Acinetobacter lwoffii F78 
APCs antigen-presenting cells 
BAL bronchoalveolar lavage  
BALF bronchoalveolar lavage fluid 
CBA cytometric bead array 
cDNA complementary DNA 
DCs dendritic cells 
Der f Dermatophagoides farinae 
Der p Dermatophagoides pteronyssinus  
DNase I deoxyribonuclease I 
dsDNA double-stranded DNA 
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ECM extracellular matrix proteins 
E. coli Escherichia coli 
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ELISA  enzyme-linked immunosorbent assay 
EPO eosinophil peroxidase 
GATA-3  GATA binding protein 3 
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GINA Global Initiative for Asthma 
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HDM house dust mite 
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KC  keratinocyte chemokine 
L(P) the length per test point 
LAR Late asthmatic reaction 
MAPK Mitogen-activated protein kinase 
 MBP major basic protein 
MCh methacholine 
min minute 
MIP2 macrophage inflammatory protein 2 
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SEM standard error 
S. sciuri Staphylococcus sciuri  
Th2 cell T helper 2 cell 
TLRs Toll-like receptors  
Tm melting temperature 
TNFα tumor necrosis factor alpha 
Treg cell regulatory T cells 
TSLP thymic stromal lymphopoietin  
VMucus the volume of GC-mucus content 
WT wild type 
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